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 While malaria cases and fatalities have fallen since 2000, there were still an estimated 
216 million cases and 445,000 deaths worldwide in 2016 -- comprising 0.8% of global deaths. 
One movement calling great attention and action to the global burden of malaria, particularly in 
sub-Saharan Africa, is effective altruism. Effective altruism is focused on prioritizing donations 
to causes and organizations with the greatest impact and highest cost-effectiveness. It hinges on 
the argument that when faced with cost-equivalent decision alternatives, we should choose those 
that do more good than less.   
The first task is to evaluate whether effective altruism is correct in its assertions and aims. 
This will rely upon philosophical discussion centered on the works of a few key effective 
altruists, namely Peter Singer, and various objections raised against the movement. The second 
task will be to understand the current state of antimalarial efforts in prevention, treatment, and 
elimination. Last, I will apply the valuable principles of effective altruism to these efforts to 
determine what methods the ideal fight against malaria would utilize.  
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Chapter I: Effective Altruism 
I.a. Background 
I recently received one-thousand dollars I didn’t deserve. This came in the form of a 
scholarship for my membership in an organization which exists primarily for social reasons. 
There were roughly sixty of these scholarships available to the organization’s members which 
were funded by alumni donations and distributed through my university. Since there are 
currently fewer than sixty members in the organization, it basically guaranteed that any member 
could earn the $1000 simply by applying. The dues for this organization were less than $1000, 
meaning members could effectively be paid for their membership. While admission is extremely 
selective, this notion was still unsettling to me. So I asked myself, what should I do with this 
money? (When I use should here, I more properly mean “what I morally ought to do.”) 
The two important words here are: what and should. What we should do (particularly 
with money) is a topic of fierce philosophical debate ranging from extreme altruistic stances of 
self-imposed poverty to ethical egoist stances that we should only spend money to further our 
own personal pursuits. The same question divides countries like the United States on partisan 
lines about the morality of uses of taxpayer money. This ponderance falls within the scope of 
normative ethics, the ethical study of what we ought to do. Depending on the answer to should, 
the question of what actually had a surprisingly defined answer. This was how I discovered 
effective altruism.  
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I.b. What is Effective Altruism? 
 Effective altruism is a guide for how we1 should consider where and what we donate to. 
As defined by William MacAskill and the Centre for Effective Altruism, “[it] is the project of 
using evidence and reason to figure out how to benefit others as much as possible, and taking 
action on that basis.”2 In The Most Good You Can Do, Peter Singer extends this definition as “a 
philosophy and social movement.”3 On the underlying principles of value theory the 
philosophical aspect focuses on comparing how much good is accomplished by different 
donations. This essentially takes form in the argument that if, all other things being equal, there 
are two donation options with the same cost but with different amounts of resultant good, it is 
morally obligatory to choose the option that does more good for the same cost.  
 In reality, effective altruism has two meanings. As discussed above, it is in itself a thesis 
in ethical theory. The other side, though, is a pragmatic, activist vision of what it means to 
employ this theory in the real world. From this social aspect, effective altruism has grown into a 
diverse community with a number of notable characteristics. As laid out by Peter Singer, 
effective altruists tend to (1) live modestly and donate a large part of their income to the most 
effective charities, (2) research and discuss charity evaluation, (3) choose a career in which they 
can earn the most in order to give, (4) talk to others about effective altruism in order to spread it, 
(5) be willing to give part of their body, such as blood or bone marrow, to a complete stranger, 
(6) have equal concern for global causes as local causes, and (7) aren’t “warm glow givers” -- 
people who give very small amounts to lots of causes for personal satisfaction. These 
                                                          
1 “We,” in this context, is referring to those of us in positions of financial security to donate without substantially 
harming our own ability to live.  
2 William MacAskill, Effective Altruism: Introduction, 2.  
3 Peter Singer, The Most Good You Can Do: How Effective Altruism Is Changing Ideas About Living Ethically, 5.  
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characteristics are not required to be part of the effective altruist community, nor must 
participants meet all of them. For example, an effective altruist can reasonably choose a career 
that pays $180k annually over a career that pays $200k because of the personal value it provides. 
An effective altruist can also rely on reputable organizations to inform his or her giving rather 
than conducting their own extensive research. An effective altruist, even, can meet none of these 
criteria while still believing in the value of the movement.  
 Singer frames effective altruism as “the most good we can do,” and subsequently attaches 
a normative claim that it is also what we ought to do. His book makes persuasive arguments, and 
in itself could be considered an act of effective altruism. To convince others to join the 
philosophical and social movement which he has helped champion, writing The Most Good You 
Can Do is a justifiable use of time and funds for the impact it could create. In that sense, we do 
have to be slightly wary of the bias Singer may hold in favor of his own goals. Contrary to 
Singer, MacAskill asserts that effective altruism is not itself a normative stance, but, rather, that 
it contains normative views within it. In other words, MacAskill does not go so far as to say 
effective altruism is the most good we can do, or that it is what we ought to do, but rather 
establishes that it is an approach to altruism that focuses on utilizing quantifiable data and 
rational decision making to do the most good. It is within effective altruism, MacAskill claims, 
that there would be a normative stance that one donation is morally obligatory over another. In 
order to best determine the application of such a philosophy, we will evaluate the tenants of these 
stances and break the argument down to its roots.  
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I.c. Breaking Down the Argument 
In order to best understand the implications of effective altruism and evaluate it properly, 
we must ascertain the components of the argument. First, let us apply working definitions to 
moral permissibility, impermissibility, and obligation. Actions are morally permissible according 
to a certain moral code if, and only if, (iff) they are actions that that moral code would deem 
acceptable. Actions that are morally obligatory are actions that a moral code would deem to be 
required to perform or else violate the moral code. For example, wearing a green shirt is morally 
permissible, but not morally obligatory. Actions that are morally obligatory are also morally 
permissible. For example, saving a child, when you have all the resources and there is no risk to 
oneself, would usually be regarded as morally obligatory (and therefore also permissible). 
Actions that are morally impermissible are actions that violate a moral code. Murder is a simple, 
common example of a morally impermissible action. We will avoid the terms right and wrong 
because their descriptive power is not specific enough for detailed ethical analysis. 
These working definitions are dependent on a moral code itself. Since establishing a 
unified moral code or theory falls outside the aim of our scope, we will utilize “commonsense 
morality.” Commonsense morality, per Shelly Kagan, is a shared “common moral outlook,” in 
which “people may differ about the details, but at least the broad features are familiar and widely 
accepted.”4 This code may include some simple, or commonsense, moral claims such as murder 
is morally impermissible or, in our case of interest, that donation is good. Of course there are 
obvious exceptions to these, such as killing in self-defense or donating to morally dubious 
organizations, but we can still start our evaluation from the basic outlook. MacAskill lays out the 
                                                          
4 Shelly Kagan, Normative Ethics, 25. 
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path that effective altruism is supported by a wide variety of moral views, saying that, “All 
plausible moral views care about making the world better, impartially speaking.”5 
 Another key component of effective altruism is value theory. Value theory is focused on 
identifying how to quantify and compare abstract concepts such as good. Much like right and 
wrong, good and bad are vague terms that can be used many ways; we need to narrow to a 
working understanding for our purposes. In his paper “Value Theory,” Mark Schroeder lays out 
four kinds of good: (1) value claims, (2) goodness simpliciter, (3) good for, and (4) attributive 
uses.6 The following sentences help exemplify their uses:  
1. Pleasure is good. 
2. It is good that you contributed. 
3. It is good for Jack to talk to Jill. 
4. That is a good knife. 
For effective altruism, the focus primarily lies on value claims and goodness simpliciter, as 
Schroeder calls it. Goodness simpliciter claims are “the ‘good’ claims that consequentialists hold 
to have a bearing on what we ought to do.”7 Relationally, this understanding of good has 
comparative power. For instance, one could say, “It is good that you did that. It is better that he 
did this.” There are a few theories for how to best understand good simpliciter, namely: the point 
of view theory and the agglomerative theory. In the way that sentence 3 shows a good for from 
the point of view for Jack, goodness simpliciter is good from the point of view of the universe. 
This theory, though, can have some undesirable conclusions such that, for the universe, it may be 
                                                          
5 MacAskill, Effective Altruism, 2. 
6 Mark Schroeder, Value Theory. 
7 Schroeder. 
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better that humans not exist at all. Under agglomerative theory goodness simpliciter is the sum of 
what is good for all the various people that there are. This is often treated as (one version of) the 
utilitarian view of good. For the sake of limiting the scope of this discussion, we will mostly 
adhere to this view of good in order to evaluate effective altruism.  
 Value claims, like the first sentence, attempt to show that things that are good are things 
that have value. In other words, their being good is what gives them value. This particular 
approach is referred to as the good-first theory. For effective altruism, this may look something 
like “donation is good” or “altruism is good.” This means we derive value from things that 
would be considered good by goodness simpliciter. The other side of this coin is the value-first 
theory which conversely says that things have value and that is what makes them good. There is 
also a difference between “intrinsic” value and “instrumental” value. Things with intrinsic value 
are good in virtue of their intrinsic properties. There is significant debate over what things are 
intrinsically good that falls outside of our scope. Things with instrumental value are good 
because they lead to other good things. For our purposes, money has instrumental value because 
of its ability to facilitate other good.  
Value claims are inherently difficult to compare. Take for example, “knowledge is good” 
and “pleasure is good.” Which is better? It is hard to determine a correct answer, or if there is an 
answer at all. Because of the difficulty to make comparisons with value claims, there is good 
rationale to avoid Singer’s normative stance that effective altruism is what we ought to do, and 
stay with the second-stage that MacAskill suggests. In other words, we can make the value claim 
that altruism is good, but we should avoid prescribing it as the best course of action and stick to 
the comparative nature of goodness simpliciter which can be used to evaluate donation 
alternatives. This, of course, weakens the stature of the effective altruist movement, but is a 
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necessary decision in order not to invalidate its self-contained claims. More on this in the 
Evaluation section.  
Effective altruism relies on the principle that donations and outcomes can be compared. 
Value theory lays out a theoretical approach to quantifying and comparing good. Pragmatically 
speaking, a number of criteria are utilized in the evaluation process, narrowing down to a 
singular scaling metric for comparison. In turn, it actually becomes more feasible to measure 
how much an action/condition damages the resting state of good. In other words, it is easier to 
say how bad things are than how good all things are. The quantifiable scaling factor for this 
burden is often called a quality-adjusted life-year (QALY) or a disability-adjusted life-year 
(DALY). Singer often uses the QALY, but based on the World Health Organization’s (WHO) 
use of the DALY, that is the terminology we will stick with. One DALY represents one lost year 
of life of full health. The WHO lays out the following formula:  
DALY = Years of Life Lost (YLL) + Years Lost due to Disability (YLD).  
YLL = N x L where N is number of deaths and L is standard life expectancy at age of death 
in years.  
YLD = I x DW x L where I is number of incident cases, DW is disability weight, and L is 
average duration of case until remission or death 
This metric is applied in the WHO’s Global Burden of Diseases for 2010 report: 
Researchers conducted nearly 14,000 face-to-face interviews in several countries and 
supplemented these findings with a web survey. The researchers found generally consistent 
results across distinct cultures. For blindness, it indicated a discount of 0.2. In other words, 
1 year when blind is equivalent to 0.8 years of healthy life, or curing a person of blindness 
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for 5 years is equivalent to extending a healthy person’s life by 1 year. At that discount 
rate… in the population we could help for $100,000, untreated blindness causes the loss of 
1000 x 0.2 = 200 DALYs per year, while starvation threatens to cause the loss of 500 
DALYs per year. On these figures, we should feed the starving.8 
There are many noteworthy reasons to be skeptical of this approach, namely in the difficulty to 
assign consistent quantitative figures to every “burden” people face. We will discuss these issues 
in depth under Challenges and Criticisms. 
The final term of the argument is “cost.” When we discuss cost, the pragmatic focus is 
largely financial. Having said that, the cost we consider ought to be inclusive of all relevant 
factors in making donation decisions. For example, making a $100 donation has an opportunity 
cost of any other action that could have been made with the $100. We ought to also consider any 
other consequences, such as the probability that our donation could have a negative impact on 
the environment or negative economic impacts such as state governments providing less aid. 
Often, these consequences are unforeseen, though, and speak to our inability to properly evaluate 
decision alternatives. More on this in Challenges and Criticisms.  
 
  
                                                          
8 Singer, The Most Good, 132. 
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I.d. Applied Examples 
Considering a few examples of the application of the theory can help bring this topic to life. 
Singer lays out an example comparing curing blindness and funding seeing-guide dogs. In total, 
supplying one person with a guide dog in the U.S. costs about $40,000. Trachoma -- the most 
common cause of preventable blindness -- can be prevented after identification for a cost ranging 
from $20-$100 per person. Per Singer, “the choice we face is to provide one person with a guide 
dog or prevent anywhere between four hundred and two thousand cases of blindness in 
developing countries.”9  
In 1998, Ted Turner gave one billion dollars to the United Nations to scale up already-
proven health programs focused on the world’s deadliest diseases, which mostly kill children. 
Singer evaluates its impact as such:  
Since 2000, 1.1 billion children have been given a combined vaccine that prevents measles 
and rubella. The vaccine now reaches 84 percent of the world’s children. Between 2000 
and 2012, worldwide deaths from measles have fallen 78 percent, with a total 13.8 million 
deaths averted. The cost per vaccination is estimated to be $1. If that figure is correct, the 
estimated cost per life saved would be just under $80.  
This example exhibits the thought process of effective altruism. The approach is largely 
systematic and rational to create the greatest positive impact, rather than utilizing a decision 
process that relies on emotion.  
 Turner’s example could stand in contrast, say, to the donation of Lucile Packard to 
establish the Lucile Packard Children’s Hospital in Palo Alto, California. This hospital is well-
                                                          
9 Singer, The Most Good, 111. 
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known for its work with separating conjoined twins; a notable nine-hour, twenty-two-person 
surgery costing an estimated $1 million to $2 million grabbed national headlines. Effective 
altruists would look to this example as a case of an ineffective use of resources that could have 
done significantly more good elsewhere. There are a number of difficult implications in reaching 
these conclusions, though, that we will evaluate in the coming sections. 
 
  
Williams  11 
 
I.e. Organizations and Current Impact 
 There are a number of existing organizations employing effective altruism to help find 
and implement solutions to the world’s most pressing problems. GiveWell and GoodVentures 
are two of the better known organizations. GiveWell focuses on researching and publishing 
details on the most effective giving opportunities and directing donations that are “evidence-
based, cost-effective and scalable.” GoodVentures is a $10 billion foundation that focuses on 
grantmaking based on three criteria: “importance, neglectedness, and tractability.” The two 
organizations partnered together and helped start the Open Philanthropy Project to advise major 
donors on maximizing their giving. 10  
In 2016, GiveWell moved over $100 million for the most effective charities; GoodVentures 
funded $126 million in grants recommended by the Open Philanthropy Project;11 Giving What 
We Can Members have collectively made over $1.5 billion in lifetime pledges to charity and 
already reported over $25 million in donations.12  
Rather than evaluating specific organizations, the Abdul Latif Jameel Poverty Action Lab (J-
PAL) and Innovations for Poverty Action (IPA) evaluate specific interventions, such as the effect 
of price on coverage of insecticide-treated bednets.13 J-PAL has a core staff of over 300 research, 
policy, education, and training professionals worldwide and receives funding from organizations 
such as the MacArthur Foundation, the Gates Foundation, the Australian Department of Foreign 
Affairs and Trade, and the UK Department for International Development. J-PAL has evaluated 
methods such as school-based deworming programs in Kenya, microfinancing in India, and 
                                                          
10 See GoodVenture’s “Grantmaking Approach” page.  
11 MacAskill, Effective Altruism, 3. 
12 This figure it tracked and displayed on GivingWhatWeCan’s homepage. 
13 Singer, The Most Good, 15. 
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improving immunization rates through regular camps. IPA has found insecticidal bednets have 
significantly better coverage when provided for free than when any cost, no matter how small, is 
distributed to recipients. The impact of its work can be seen in the WHO’s endorsement of free 
nets, in certain organizations’ movement to provide free nets in endemic areas, and Population 
Services International’s (PSI) decision to rapidly scale up free nets for high risk groups such as 
pregnant women.14  
The organizations detailed here name a few notable examples, but only serve to show the 
growing trend of effective altruism and the scale of impact it is creating.  
 
  
                                                          
14 Per IPA’s summary of results on providing free bed nets. https://www.poverty-action.org/impact/free-malaria-
bednets  
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I.f. Challenges and Criticisms 
Denouncing Good for Better  
Within its root ambitions, effective altruism presents us with a number of challenges. 
First, it lays out a view for how to give effectively for those individuals who are committed to 
donation. This is formulated in a two-step structure: Step One being the decision to give and Step 
Two being the decision of what to give to. This could be a decision to donate a percentage of 
one’s income every year, meaning the dollar amount is fixed and there is a second decision of 
where to donate the money. While this is an accurate description of some individuals’ decision-
making process, many individuals’ charitable choices are motivated emotionally and carried out 
in a single-step procedure. In other words, sometimes one doesn’t decide just to give but rather 
decides to give to a certain cause. This is often done on the basis of some emotional or personal 
connection to a cause.  
Within the normative stance of moral obligation to choose efficient options, this leaves us 
in the uncomfortable position of criticizing/denouncing actions that are still charitable but to 
lesser degrees. It is hard to foresee the overall impact of such a stance, but one possibility is a 
decrease in overall donation amounts. Take for example someone who is interested in helping 
maintain the public library system in his or her city by donating money. If effective altruism 
were widespread and accepted, this person may feel too much shame or judgement for making 
that donation and instead do nothing altruistic with that money. That would result in a net 
negative under almost any working application of good. Take another situation in which your 
neighbors approach you that their child has been diagnosed with a form of cancer and asks for 
any donation that you could manage in order to help pay for treatment. Even knowing that you 
could save more children elsewhere in the world with the same money, would you really feel 
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good turning them down on such a basis? You would probably seek to help your neighbor first, 
meaning this money may come funds you had intended to do more with. If not, it could condition 
us to earmark less to charity in advance because we can foresee events like this.   
Melissa Berman, the president and CEO of Rockefeller Philanthropy Advisors, an 
organization Singer critiques, “explain[ed] why it is best to allow potential donors to follow their 
‘personal convictions’ in choosing a charity. Doing so leads, she observes, to their giving more 
and more consistently.”15 Even if this is true, it does not necessarily mean that more good cannot 
still be done with less. For example, an effective $50 donation may help more people more 
significantly (think DALYs) than an ineffective $100 donation. Having said that, since this 
figure is difficult to quantify precisely we cannot rule it out of consideration against effective 
altruism.   
Terms of the Argument 
Challenges also lie in the difficulty of precisely defining terms within the argument and 
how they should be applied in the real world. In the real world moral choices do not always fall 
into an easy bucket of morally obligatory, morally permissible, and morally impermissible. We 
disagree amongst ourselves on a number of moral topics such as abortion, capital punishment, 
the role of governments, and the “costs” of certain freedoms like the First and Second 
Amendment. Categorizing our decisions within these buckets is, in itself, an entire debate, of 
which effective altruism makes some presuppositions. Defining and quantifying good may be the 
most difficult. Effective altruism relies on the work of value theory to establish value claims and 
comparative good through goodness simpliciter, but there is fair disagreement with these 
                                                          
15 Singer, The Most Good, 125. 
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principles entirely in the philosophy community. For example, can we really say that some acts 
are “better” than others or just that they are “good?” 
Quantifying and Comparing Good 
The effort to quantify that decision with metrics such as a DALY presents problems as 
well. Inherently, there can be no DALY that is truly correct. We often must use averages based 
on interviews and surveys based on how people think they would make tradeoffs between 
different conditions such as blindness and deafness. For every person the answer is different, 
though. More so, we have significant evidence from psychological research pointing to the 
unreliability of healthy individuals making judgments about what it would be like to suffer from 
certain conditions.16 What this leaves us with, often, is precise results from imprecise inputs. For 
example, for the global disease burden, the DALYs for a certain disease can shift drastically on 
small changes in the discount rate. For example, certain blind individuals saying that one year of 
living with blindness is worth 0.8 years of healthy life helps us build a guideline but can it be 
compared to, hypothetically, different individuals suffering from paralysis saying it is worth 0.75 
years of healthy life? Is there not a significant margin of error here for people’s inability to 
accurately pinpoint such a precise figure? These judgements are largely emotional and subject to 
bias. A more reliable way to build out comparisons would be to find single individuals suffering 
from more than one disease in order to compare from a single standpoint, but finding such 
individuals can be quite difficult -- if they exist at all -- for certain comparisons. Additionally, 
this fails to consider whether we place any significance on an individual having a causal 
relationship with their burden. A commonly-analyzed population is the inmate population in the 
                                                          
16 Donald Redelmeier and Daniel Kahneman, “Patients’ Memories of Painful Medical Treatments: Real-time and 
Retrospective Evaluations of Two Minimally Invasive Procedures,” Pain 66:1 (1996): 3-8, and Donald Redelmeier, 
Joel Katz, and Daniel Kahneman, “Memories of Colonoscopy: A Randomized Trial,” Pain 104 (2003): 187-194. 
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U.S. and the DALYs lost every year to the prison system. While there are certainly non-violent 
offenses that are over-punished and innocent individuals who are wrongly imprisoned, it would 
make sense to very few people to suggest releasing all prisoners back into society to reduce the 
collective DALYs lost.  
Focusing on evaluating and producing quantifiable metrics for comparison can also have 
negative consequences what we give to. Steven Brown provides a critique of the implications of 
focusing on metrics: 
GiveWell’s methodology prioritizes easily measurable metrics, and those outcomes that 
can also be researched and tracked in a particularly rigorous way. This leads to their most 
serious drawback: overlooking projects that should be a high priority, but are difficult to 
measure. When one takes a step back and asks what it would take to better a place that is 
not doing well, one will surely come across many difficult to measure answers. For 
example, it is striking that since it began giving ratings in 2008, GiveWell has only 
recommended a single international educational charity… education is certainly one of the 
most important things a community must have if it is to rise out of poverty and not merely 
survive.”17 
Metaphorically, Brown’s point suggests that effective altruism is applying bandages to wounds 
but not taking necessary action to heal the underlying injury. The focus on metrics and evidence 
points to an issue voiced by Emily Clough in “Effective Altruism’s Political Blind Spot.” She 
criticizes effective altruist groups’ reliance on randomized control trials (RCTs) saying that an 
RCT “might determine whether a bed net distribution program lowered the incidence of malaria 
                                                          
17 Steven G. Brown, “Supporting the Best Charities is Harder than it Seems.” Journal of Global Ethics 12, no. 2 
(2016): 242, 240-244. 
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among its target population. But it would be less likely to capture whether the program 
unintentionally demobilized political pressures on the government to build a more effective 
malaria eradication program, one that would ultimately affect more people.18  
In face of all the criticism presented of using RCTs and the DALY as a metric, its 
theoretical and pragmatic benefits still make sense to Toby Ord, the founder of Giving What We 
Can, to whom it represents the “best effort so far” to make a comparative metric for healthcare 
intervention. Additionally, it still remains the WHO method for estimating the global disease 
burden which provides participants in this realm a consistent basis for data.   
Unforeseen Results 
 One criticism to the highly-targeted donation of effective altruism is the difficulty to 
account for unforeseen results. As Brown mentioned, focusing on DALYs and RCTs can create a 
lack of focus on non-quantifiable risks. For example, as Emily Clough mentioned, “The presence 
of NGOs induces exit from the state sector… the pressure on the government to maintain and 
improve services eases, and the quality of government provisions is likely to fall.”19 This effect, 
oftentimes called skimming, can have consequences for the poorest individuals who lack 
awareness of non-government organizations’ (NGOs) efforts to provide services. As a result of 
the reduced pressure by citizens on the state to provide quality healthcare, education, and 
protection, the quality of government provision is likely to fall. Clough concludes that: 
[Effective altruists] must contend with the fact that the state remains the primary provider 
of basic social welfare for most poor citizens in most poor countries, and that pumping 
                                                          
18 Emily Clough, Effective Altruism’s Political Blind Spot, Boston Review, 14 Jul 2015. 
19 Clough. 
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money into a parallel set of providers—even good ones—without a plan for reaching the 
coverage or scale of a state may do serious harm to the poor who are left in the state 
system.20 
Clough suggests not only that effective altruists be more considerate in their factors, but 
specifically that they look towards funding advocacy and watchdog groups in certain countries. 
Particularly in countries where governments don’t allow advocacy groups to receive funds from 
foreign governments but which can accept contributions from private organizations.  
 Another, more directly attributable risk has been realized in the last several years: 
Insecticide-treated nets used to combat malaria were also being used by fishermen across the 
world, particularly in tropical areas such as East Africa where malaria is the most prevalent. 
There isn’t causal data to show whether this is a result of the growing availability of free nets, in 
particular. Regardless, there is sufficient information to know that this poses a health risk to both 
humans and the fish stocks. The latter is predominantly because the nets are so finely woven that 
they catch even the small, young fish. The exact impact of these findings isn’t yet known, but it 
calls for greater research in this area.21 This particular unforeseen consequence may stand out to 
effective altruists given the popular ranking of malaria nets as a cost-effective intervention 
method. GiveWell, for example, ranks the Against Malaria Foundation -- a distributor of long-
lasting insecticidal nets -- in its top tier of charities.  
 
 
                                                          
20 Clough. 
21 Damian Carrington, Global use of mosquito nets for fishing ‘endangering humans and wildlife, (The Guardian, 
2018).  
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Personal Moral Judgements 
Limiting effective altruism to the second step of the donation process (deciding what to 
donate to after already deciding to donate to something) still requires us to make some moral 
judgements in order to compare causes. In a blog post, Holden Karnofsky -- a founder of 
GiveWell -- put forth three scenarios: 
1. Prevent 100 deaths-in-infancy, knowing that in all likelihood these 100 people will grow 
up to have consistently low income and poor health for a 40 year lifetime 
2. Provide consistent nutrition and health care to 100 people, such that instead of growing 
up malnourished they spend their lives healthy. (Assume for simplicity that their lifespan 
is also 40 years.) 
3. Prevent one case of relatively mild non-fatal malaria (say a fever that lasts a few days) 
for 10,000 people without having a significant impact on the rest of their lives 
Holden chooses (2) because he is “very excited by the idea of changing someone’s life in a 
lasting and significant way.” He rejects (3) because he doesn’t think quality of life consists 
simply in the sum of the quality of days in it. He rejects (1) because he does not put much value 
on “potential lives,” especially when the lives may be filled with health problems.  
Holden’s decision shows how different people may reach different conclusions based on 
personal moral judgements. Even if DALYs were assigned to all of these (say option 3 was the 
highest for example), he may still opt for (2) because of his own moral and logical beliefs. This 
points to a characteristic of effective altruism -- the lack of a consistent, underlying moral code. 
On one hand, this leaves individuals with room to apply their own beliefs and become more 
impassioned in their giving. It also provides a diverse approach of methods and causes. On the 
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other hand, the lack of a consistent moral philosophy can weaken the effectiveness of the 
movement and the organizations that represent it. If effective altruist organizations want to be a 
recipient of donation in order to reroute funds effectively, they must show that they function 
under some consistent moral code. 
One of the large divides within effective altruism lies within how to view animal 
suffering. While most would agree that animal suffering matters, comparing it to human 
suffering is a difficult task. This opens up questions such as: Should animal suffering count the 
same? Do animals consciously process suffering the way that people do? Do they have a 
capacity for suffering? Do humans suffer differently from one another? The difficulty of 
answering these underlying moral questions of causes is evidenced by various effective altruist 
organizations ranking different causes and charities at different levels.  
Another significant issue which effective altruists cannot come to agree on is whether to 
donate or to invest (for future donation). In other words, is it better to donate $1 million today or 
invest the $1 million to let it grow and be able to donate more money later? The primary 
arguments for investment are: (1) more money can have a greater impact later, (2) it provides 
more time to determine what the most efficient investments are, (3) greater ability to fund 
specific projects -- i.e. if a new intervention is uncovered for a region and needs a certain amount 
of funding, you can contribute more -- and (4) the bargaining power of more funding allows us to 
demand greater transparency.   
The arguments in favor of donating now are primarily: (1) compounding benefits of 
current investment -- for example, the benefit of opening a school today compounds as time 
progresses and the benefit at year five is not equivalent to the benefit if it was opened at year 
five, (2) network effect -- seeing donation may encourage others to give going forward, (3) the 
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best donation opportunities may disappear, (4) reduces the risk that you may become less 
altruistic and not donate all the money later, and (5) deferring donation for investment may 
become indefinite -- the next year it will always be more money, so when do we actually use it? 
There are some hybrid solutions to this issue such as giving now to meta-charities like GiveWell 
so they can appropriately distribute funding in the most effective amounts (due to some of the 
compounding benefits mentioned earlier).22  
Normative Incompletion 
Stepping away from only evaluating the second step of donation, there is some criticism 
that effective altruism is incomplete as a normative movement. This is considered in the sense 
that the same actions and lessons of effective altruism should be applied in other aspects of life. 
A few notable movements are selective asceticism, ethical consumerism, and the moral market. 
While effective altruism deems donation the best way to intervene in solving the world’s 
pressing problems, these other movements focus on the non-donation-based actions we can take.  
Selective asceticism calls for individuals to take strategic inaction to combat the world’s 
issues. In her paper on selective asceticism as “the other half of effective altruism,” Kathryn 
Muyskens says that, “effective altruists need to take seriously the ways in which their actions 
contribute to systemic inequality and structural violence. Donation is not enough to create a 
paradigm shift or to stop systemic injustice.”23 This could include inactions like not eating meat; 
which could logically be paired with the effective altruist position to support charities against 
animal cruelty.  
                                                          
22 Bastian Stern, Donating vs Investing, (GivingWhatWeCan, 2012). 
23 Kathryn Muyskens, The Other Half of Effective Altruism: Selective Asceticism, (Essays in Philosophy, 2017), 2.  
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Ethical consumerism would call for individuals to consume things (food, entertainment, 
etc.) that are ethically sourced. On the vegetarian example, buying vegetables that were grown 
on farms with fair wages and taking measures to protect the environment.  
The moral market is a largely conceptual market (mostly being tested at universities) in 
which our entitlements can be bought. Entitlements are actions we are permitted to do or not do. 
From a normative point of view, a moral market could suggest that we ought to pay others to 
cease behavior that we believe is morally impermissible which they are morally indifferent 
towards. While this could conflict with a normative view of effective altruism because it calls for 
us to put our money towards buying entitlements rather than toward donation, I think it can work 
together with effective altruism in the cases that the moral market is more efficient to accomplish 
good. In the vegetarian example, this would involve paying people to not eat meat. There are 
numerous reasons a moral market may be problematic and not pragmatic, but that evaluation 
falls outside the scope of what we want to accomplish here with effective altruism.  
Is it Inhumane? 
The concern that there may be something inhumane about effective altruism is a pressing 
issue for both the philosophy and movement. In “Effective Altruism and the Altruistic 
Repugnant Conclusion,” Gianfranco Pellegrino argues: 
Compared to a possible charitable action a, whereby a given amount of benefit is given to 
a great number of people, there must be some alternative charitable action b that, at the 
same cost, can give a much greater amount of very tiny benefits to a much larger number 
of people and that, if other things are equal, should be preferred to a.24 
                                                          
24 Gianfranco Pellegrino, Effective Altruism and the Altruistic Repugnant Conclusion, (Essays in Philosophy, 2017).  
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Pellegrino refers to this as the Altruistic Repugnant Conclusion (ARC). His argument against 
effective altruism is complex -- I will try to simplify it while making an active effort not to create 
a strawman. At its root, Pellegrino argues that effective altruism, particularly based on Holden’s 
decision (which I have provided above under Personal Moral Judgements), can lead us to make 
choices that would favor small benefits towards many rather than significant benefits to a few. 
This decision, he argues, is repugnant in that puts minor, unnecessary benefits before the true 
needs of others. ARC, he argues, is not an unrealistic occurrence for effective altruism either:  
It is perfectly possible that current aid strategies will lead to an overcrowded world of 
illiterate people, living very poor lives, even though being saved from some days of 
avoidable morbidity. If this scenario appears to us repugnant, this is not due to its being 
unrealistic.25 
Singer briefly addresses this notion when he discusses Thomas Scanlon’s argument of 
‘justificatory weight.’ An example is proposed in which a technician for a televised event suffers 
a serious injury and the only way to help him is to stop the broadcast. Scanlon asserts that it 
doesn’t matter if a billion people are watching; the sum of the smaller pleasures of the many 
have no ‘justificatory weight’ compared to the needs of the severely burdened.26 This seems like 
a promising workaround to Pellegrino’s repugnant conclusion, but it contains some problems in 
itself. First, defining the ‘severely burdened’ may be difficult. Are only fatal conditions severe? 
It also does not address comparing some burdens to others (such as deafness vs blindness) rather 
than to an absence of pleasure. What both Scanlon and Pellegrino seem to be angling at, though, 
                                                          
25 Gianfranco. 
26 Singer, The Most Good, 120. 
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is that there are certain utilitarian conclusions that may be associated with effective altruism that 
defy some intuitive or commonsense morality. More on this in the Evaluation section. 
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I.g. Evaluation 
 “It was impermissible to donate to that children’s hospital.” Framed like this, there is a 
significant part of me that has a negative gut reaction to some of the conclusions of effective 
altruism. It seems incredibly difficult (emotionally speaking) to reach some of the conclusions 
which prioritize certain lives over others based on financial viability. It seems to me that there 
should be a valid effort to save every life. In a world where many people fail to contribute 
anything to those in need, saying that someone’s decision to do good, such as donating to a 
children’s hospital focused on separating conjoined twins, is morally impermissible seems 
counterintuitive -- or at minimum unforgiving. This is why it’s important to sort out what the 
philosophy actually says as opposed to strawman arguments that overextend the principles of the 
movement. The real basis of the effective altruist argument is that, all else being equal, we 
should do more good than less when given the opportunity. There is nothing wrong with making 
emotional donations in the one-step process we have detailed earlier. Effective altruism, in the 
form we have laid out, should come into effect if there is a two-step structure and it only says 
that if we are looking at various recipients for donations, we should pick those that are the most 
efficient.  
I’ll elaborate. Having laid out the first-level normative stance of Singer and the second-level 
stance of MacAskill, it seems wiser to apply the tenets of the second level. It may seem puzzling 
to say that it is morally permissible to not donate anything (and do no good) yet it is not morally 
permissible to donate to less efficient causes, but Derek Parfit provides a good example to why 
this can be true: 
“Suppose that I have three alternatives:  
A: at some great cost to myself, saving a stranger’s right arm;  
Williams  26 
 
B: doing nothing;  
C: at the same cost to myself, saving both the arms of this stranger.”27 
Parfit’s claim here is that, while one would not be morally obligated to take the great cost to 
oneself to save a stranger’s arm, if one did decide to take on the cost, he or she would be morally 
obligated to save both arms of the stranger since it poses no additional cost. In light of criticism 
that this argument is ineffective because there is no tradeoff cost to do C, Shelly Kagan offered 
another scenario. Facing a burning building, if one made the decision to enter it and found a 
trapped bird and child (and only one could be saved), one would certainly be obligated to save 
the child. In this sense, the tradeoffs are made at the second level. The decision to not enter the 
building is not itself morally impermissible based on the potential harm, but if one undertook the 
risk, saving the bird would be an impermissible choice.  
In this sense, we should implement at the second order of, “I have decided I’m going to 
give… Now what should I give to?” Isolating to this level allows us greater freedom to apply the 
principles of effective altruism without having to adhere to a number of other movements and 
conclusions outside the scope of effective altruism, such as selective asceticism and ethical 
consumerism.   
Let me take this opportunity to offer a realistic donation case that supports this point. If a 
homeless individual approaches me and asks for money, it is not impermissible to give him 
money so long as that money doesn’t come from funds I would have donated elsewhere. If that 
meant forsaking my morning coffee when I otherwise wouldn’t have, then the net altruistic 
impact is still positive. One could reasonably argue that that act was still a good act, and not 
                                                          
27 Derek Parfit, Future Generations: Further Problems, (Philosophy and Public Affairs 11, 1982), 131.  
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wrong at all. Now, if while sitting at home I made the choice that I would go search for a 
homeless man to give $10, we would be critical of this decision considering the comparative 
impact of $10 elsewhere in the world -- this money may only buy the man a single lunch whereas 
it could provide a child immunization to a number of diseases elsewhere in the world. By 
utilizing effective altruism at the second level, we can avoid making judgements on good acts 
with emotional motivations (that would not have happened without an emotional stimulus) and 
focus on the best ways to apply money that has been earmarked for altruistic purposes.  
 In concluding my evaluation here, it should be said that a true form of effective altruism 
is effectively impossible and only exists in theory. With the theoretical form of effective altruism 
we would always know which decisions bring the most good and what their consequences are; 
every alternative would be quantifiable and wouldn’t use flawed metrics like the DALY; and our 
underlying moral judgements and values wouldn’t have a significant impact on which causes we 
prioritize. Unsurprisingly, we do not live in a world in which we always make the best decisions, 
let alone a world in which we are able to quantify every aspect of said decisions. In spite of these 
challenges, there are benefits to a pragmatic form of effective altruism. When confronted with a 
set of choices, very few would argue that it is wrong to seek to do more good than less. The idea 
of comparing donation options to do the most good, no matter how imperfect, is better than the 
alternative of trying not do more good when possible.  
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I.h. How We’ll Apply It 
Looking to apply effective altruism means looking to the areas of the world most in need 
of aid. Per WHO estimates, the global DALYs per 100,000 population sat at 36,331 DALYs in 
2015. The WHO Africa region had an estimated 63,349 DALYs per 100,000 in 2015 which was 
significantly higher than any other region. (The WHO Eastern Mediterranean region ranked 
second at 38,211 per 100,000.) This figure for Africa is down significantly from 107,065 in 2000 
which suggests that actions taken in the last few decades have made significant progress in 
bettering lives in that region. It also signals that we can continue to target certain areas in order 
to reduce Africa’s disease burden to levels in line with the rest of the world.28  
Again, I must re-mention that DALYs are a flawed metric for a number of previously-
detailed reasons, but I think they still merit some pragmatic use as a guide to identifying which 
areas carry high burdens relative to the rest of the world and how we can act.  
The WHO Global Health Estimates 2015 report shows increases in deaths caused by 
most cancers globally from 2000 to 2015. Malignant neoplasms, as the WHO classifies them, has 
grown from roughly 7 million deaths in 2010 to nearly 8.8 million deaths in 2015. Crude death 
rates (CDRs) and age-specific death rates (ASDRs) are relatively flat or slightly decreasing for 
most cancers over the same time period. The fight against cancer is certainly an important one, 
but it is not one to which I can significantly contribute to here. Death counts continue to rise in 
spite of growth in funding.29 This isn’t to say the funding isn’t effective or worthwhile, but only 
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29 Eckhouse et al., Trends in the global funding and activity of cancer research, (Molecular Oncology, 2008). 
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to say that cancer research has a step-function structure in which meaningful developments come 
from breakthroughs rather than the marginal effects of day-to-day activities.    
Malaria, meanwhile, has seen a 49% reduction in attributable deaths from 2000 to 2015 
(down from 859,000 to 439,000). As a percent of total global deaths, malaria’s share has fallen 
from 1.7% to 0.8%. Accordingly, the CDR and ASDR of malaria have both fallen by more than 
half. While it is difficult to accurately quantify the exact amount of total funding going to these 
causes, we can feasibly conclude that malaria has a high level of preventability and reducibility. 
In the following section we will summarize the attributions of the falling mortality rates of 
malaria and seek to apply tenets of effective altruism to our findings. The purpose of such an 
effort is to determine which efforts in the fight against malaria are the most effective and deserve 
the most backing. This is not to say that there aren’t other areas worth consideration. To name 
just two, the number of DALYs lost to the HIV/AIDS epidemic (45,870 in Africa) or diarrhoeal 
diseases (44,483 in Africa) merit attention and action.  
As we continue to battle the great afflictions facing humanity, such as cancer, I can’t help but 
feel that we’ve left behind a significant portion of the world that is still afflicted with very 
pervasive, and very preventable, health threats. For the scope of this essay, I wanted to spend 
time in the following sections exploring malaria for two primary reasons: (1) it significantly 
affects young children without the agency to defend themselves -- age is a large reason why the 
DALY count is so high for malaria -- and (2) there are a large variety of methods being 
employed that we can look to evaluate.  
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Chapter II: Malaria 
II.a. Disease Background 
Epidemiology 
 “Malaria,” as we commonly know it, is a disease caused by plasmodium parasites which 
are spread through the bites of infected female Anepholes mosquitoes, which act as “malaria 
vectors.” Female mosquitoes bite humans to take “blood meals” in order to gain nutrients to 
develop eggs; male mosquitoes do not bite humans. The plasmodium parasites successfully 
infect two hosts: humans and female Anepholes mosquitoes. There are five parasite species that 
cause malaria in humans. The two in particular that the World Health Organization (WHO) 
recognizes as posing the greatest threat are Plasmodium falciparum and Plasmodium vivax. P. 
falciparum, for short, is the most prevalent malaria parasite on the African continent and 
responsible for the most malaria-related deaths globally. P. Vivax is the most dominant malaria 
parasite in most countries outside sub-Saharan Africa.30 
 In humans, the plasmodium parasites initially grow and multiply in the liver cells before 
expanding into red blood cells.31 In the blood, the parasites destroy the red blood cells and 
release “meterozoites,” that continue the cycle of infecting and destroying other red blood cells. 
The parasite burden expands logarithmically by approximately ten-fold per 48-hour cycle.32 The 
blood stage parasites are responsible for the symptoms associated with malaria. When these 
“gamocytes” are picked up by the female Anopheles mosquito, they start a new cycle within the 
mosquito. After 10-18 days, the parasites are considered “sporozoites” and found in the 
                                                          
30 These claims are all detailed in the WHO Malaria Factsheet 
31 Per the CDC’s “Biology of Malaria” page 
32 This figure is specifically based on studies of P. falciparum. See Simpson et al., 2002; White, 2004 
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mosquito’s salivary glands. When the mosquito takes a “blood meal” on a human, these 
sporozoites are injected into the humans which then target the liver cells. And so ensues the 
cycle. Notably, the mosquito acts solely as a vector and does not suffer from the parasites.33   
Symptoms 
Malaria is an acute febrile illness that carries with it a number of symptoms which can be 
different for children and adults. In general, symptoms appear 10-15 days after infection. 
Symptoms of malaria “include fever and flu-like illness… shaking chills, headache, muscle 
aches, and tiredness. Nausea, vomiting, and diarrhea may also occur.”34 Malaria may also lead to 
anemia and jaundice as a result of the diminished red blood cell count. If not treated within 24 
hours, malaria can progress to severe illness “including kidney failure, seizures, mental 
confusion, coma, and death.”35 Children, particularly, experience severe anemia, respiratory 
distress in relation to metabolic acidosis, and/or cerebral malaria. P. vivax and P. ovale have 
potential to relapse up to 4 years later as dormant parasites in red blood cells reengage.36  
It is not uncommon for individuals in malaria endemic areas to develop partial immunity. 
This means that infection can be harder to determine based on asymptomatic infections 
(infections that don’t manifest in the usual symptoms).   
Impact and Costs 
According to the 2017 World Malaria Report, an annual document prepared by the WHO 
Global Malaria Program, nearly half the world’s population is at risk of contracting malaria. In 
                                                          
33 See Appendix A for a detailed illustration of the cycle. 
34 Per the CDC’s “About Malaria” page  
35 Per the CDC’s “About Malaria” page 
36 Per the CDC’s “About Malaria” page 
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2016, 91 countries reported 216 million cases of malaria and 445,000 deaths due to the disease. 
285,000 of these deaths were attributable to children under the age of 5. This figure is down from 
440,000 deaths of children under the age of 5 in 2010. The United States saw 1700 cases of 
malaria, attributed mostly to travelers returning from overseas.  
 The WHO African Region accounts for roughly 90% of malaria cases and deaths 
worldwide, with 15 countries carrying 80% of the global malaria burden. All but one of those 15 
countries is in sub-Saharan Africa. According to the CDC, “in Africa alone, costs of illness 
treatment, and premature death from malaria are at least $12 billion per year.”37 Additionally, 
malaria has been shown to reduce the gross domestic product of endemic countries by several 
percentage points.38  
 Information regarding impact and costs is primarily obtained through reports from 
national malaria control programs (NMCPs) in the 94 countries with malaria transmission in 
2000. Supplemental data is attained from nationally representative household surveys and 
databases held by other organizations participating in the Alliance for Malaria Prevention; the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund); the Organization for 
Economic Co-operation and Development; Policy Cures; the US President’s Malaria Initiative; 
and WHO. Due to the depth of sources utilized by the WHO in the World Malaria Report, this 
document will serve as a principal source of data and figures for estimating impact, scope, and 
outlook of various aspects of the fight against malaria.  
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II.b. Aims 
Goals and Outlook 
 The World Malaria Report sets out a number of goals and targets, specifically in the 
“Global technical strategy for malaria 2016-2030 (GTS)” and the “Roll Back Malaria advocacy 
plan, Action and investment to defeat malaria 2016-2030 (AIM).” These goals align with the 
United Nations’ “Sustainable Development Goals (SDGs)” which entails a “plan of action for 
people, the planet and prosperity.”39 The goals set in the GTS and AIM are targeted for 2020, 
2025, and 2030 with a baseline comparison to 2015.  
 These goals and targets can be found in Appendix B. The most notable targets are to 
reduce both malaria mortality rates and malaria case incidence globally by at least 40% in 2020, 
75% in 2025, and 90% in 2030 relative to 2015 figures.40 According to the CDC, scale-up of 
malaria prevention and treatment interventions has saved 6.8 million lives globally from 2000-
2015 and mortality rates due to malaria in Africa over that period were cut by more than half.41  
The goals of GTS and AIM face a number of self-identified threats and pressures 
including: inadequate funding, evolution of resistance of parasites to drugs and vectors to 
insecticides, and the interruption of inventions due to complex situations such as insecurity.  
With data only going through 2016, it is too early to say whether the targets established 
in 2015 are on course. Looking back at the period of 2010-2016 can indicate how the 
significance of malaria is already trending. In that period, the world saw a 32% decrease in the 
malaria mortality rate (deaths per 100,000 population at risk). In Africa, the mortality rate has 
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declined every year since 2010 and sits at 43% as of 2016. The trend for the world malaria 
mortality rate isn’t as strong, but currently sits at 12.9%. Of the 15 countries with nearly 80% of 
the malaria burden, Nigeria accounts for 30% of estimated malaria deaths followed by the 
Democratic Republic of the Congo which accounts for 14%.42  
Investment 
In 2016, an estimated $2.7 billion was invested in malaria control and elimination efforts 
-- short of the WHO minimum target investment of $6.5 billion. Per the WHO, investment would 
need to reach the level of $6.5 billion annually by 2020 in order to meet the long-term GTS 
targets for the fight against malaria. Outside of the affected regions, the United States contributed 
the most funding: $1 billion (38%), followed by the United Kingdom and other donors including 
France, Germany and Japan. Governments of endemic countries contributed $800 million (31%) 
of the $2.7 billion in funding. 57% of international funding was channeled through the Global 
Fund in 2016.43  
Total research and development (R&D) funding was estimated at $575 million in 2015 
which accounts for 83% of the estimated $686 million annual funding required for R&D to meet 
GTS targets. 2014 funding was higher than usual due to a large disbursement from the Bill and 
Melinda Gates Foundation for vaccines. Funding decreased across certain groups, namely: the 
Australian National Health and Medical Research Council, the Wellcome Trust and the 
European Union. Among the private sector and US Government Agencies, R&D funding 
increased primarily in the area of drug development. Over the last 3 years, the three main 
funding channels have been the US Government National Institutes of Health (27% of total 
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funding), the Bill & Melinda Gates Foundation (22%), and biotechnology companies (21% 
collectively). Appendix C provides a thorough breakdown of sources of funding and research 
areas.   
Methods to combatting malaria generally fall in one of three categories: Prevention, 
Treatment, or Elimination. Prevention and treatment are primarily aimed at reducing incidences 
of malaria, whereas elimination is focused on methods to eliminate risk of the disease entirely.   
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II.c. Prevention Methods 
 The primary methods of malaria prevention currently employed are: insecticide-treated 
bed nets (ITNs), which includes long-lasting insecticidal nets (LLINs); indoor residual spraying 
(IRS); vaccines -- particularly the PATH Malaria Vaccine Initiative; and seasonal malaria 
chemoprevention (SMC).  
Bed Nets: ITNs and LLINs 
The first major prevention method, ITNs and LLINs, have shown in trials to reduce the 
deaths of children under 5 by approximately 20%.44 These bed nets repel and kill mosquitoes and 
other insects, protecting sleeping individuals from mosquitoes carrying malaria. Per the WHO, 
54% of people at risk of malaria in sub-Saharan Africa were sleeping under an ITN in 2016. This 
figure has increased substantially from 2010 to 2016.45 Nets are currently the primary method of 
prevention in the form of ITNs and LLINs, which differ from ITNs in that they are designed to 
remain effective for multiple years without retreatment. Studies show that LLINs can also save 
up to $3.8 billion over 10 years by reducing the need for retreatment from 3 to 5 years.46 Per the 
CDC, ITNs compound into a community-coverage effect which can protect all members of a 
community (even those not using nets) when over half of the community uses nets.47 Net-based 
prevention methods are a primary driver of the cost-effectiveness of treating malaria and 
according to GiveWell’s analysis of the Against Malaria Foundation (AMF), AMF can produce 
and distribute LLINs for an estimated $4.22 in most regions.48 Per the WHO, 582 million ITNs 
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46 Per the CDC page on ITNs 
47 Per the CDC page on ITNs 
48 Per GIveWell’s cost analysis of the Against Malaria Foundation.  
Williams  37 
 
were delivered globally between 2014 and 2016. This marks significant growth from the 
previous three year period (2011-2014) in which 301 million ITNs were delivered. 16 countries 
in sub-Saharan Africa accounted for over 80% of deliveries in the most recent three year period. 
ITNs are primarily distributed through mass campaigns (75% of distribution) with additional 
distribution occurring through antenatal care clinics (13%) and alongside child immunization 
(5%). The latter two allow for nets to be distributed to the two most malaria-susceptible groups: 
pregnant women and children.  
Indoor Residual Spraying 
While the coverage of nets is up significantly from 2010, indoor residual spraying (IRS) 
has declined significantly over the same period. See Appendix D for the contrasting trend lines. 
Because mosquitoes have shown tendencies to rest inside domiciles post blood meal, IRS has 
potential to be effective at controlling indoor mosquito populations. Because IRS kills 
mosquitoes that come in contact with walls and other sprayed surfaces, it is not a direct method 
of prevention. Rather, IRS is effective at preventing mosquitoes from transmitting plasmodium 
parasites to other humans because of the tendency to rest inside buildings after biting individuals. 
To produce effective results, IRS must be implemented in a high percentage of households, 
usually over 80%. Indoor residual spraying fell out of popularity following concerns over the 
environmental impact of DDT, but interest has renewed with the success of IRS in South Africa 
at reducing malaria incidences by more than 80%.49  
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Vaccinations 
Another prevention method receiving funding with high aspirations is malaria 
vaccination. The only currently approved vaccine is RTS,S which requires four injections and 
has a relatively low efficacy ranging from 26-50%. RTS,S was developed by PATH Malaria 
Vaccine Initiative (MVI) and GlaxoSmithKline (GSK) with aid from the Bill and Melinda Gates 
Foundation. Per the WHO, the median of 4 models of cost effectiveness for the RTS,S 
vaccination in a 4-dose schedule is $87 per DALY averted (assuming $5 per vaccine).50 Per the 
WHO, “These estimates are consistent with the cost per DALY averted for other vaccines in a 
broad range of developing countries.”51 On the basis of DALYs as a metric, WHO estimates the 
RTS,S vaccine as an effective method after LLINs and seasonal malaria chemoprevention 
(escalating preventative measures during malaria season) achieve high usage and coverage. 
Based on shifting efficacy among age groups, WHO particularly does not recommend the RTS,S 
vaccine among children of age 6-12 weeks.52  
Seasonal Malaria Chemoprevention 
Season malaria chemoprevention (SMC) targets P. falciparum in highly seasonal 
transmission areas in the Sahel sub-region of sub-Saharan Africa. Following WHO 
recommendations in 2012, SMC implementation was scaled up in 2015 and 2016 via door-to-
door distribution which has proved to be more effective than fixed distribution points.53 The 
seasonal malaria chemoprevention method entails “maintaining therapeutic antimalarial drug 
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52 Per the WHO Malaria Vaccine Position Paper, p50. 
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concentrations in the blood throughout the period of greatest malarial risk.”54 This is specifically 
targeted towards children and achieved by using antimalarial drug treatments containing 
sulfadoxine-pyrimethamine and amodiaquine. Effective antimalarial treatment in monthly 
intervals “has been shown to be 75% protective against uncomplicated and severe malaria in 
children under 5 years of age… [and] is cost-effective and safe and can be administered by 
community-health workers.”55  
Approximately 15 million children were included in SMC programs in 2016 with 60 
million monthly treatments administered. This represented a 91% inclusion rate for children in 
areas where SMC programs were established.56 This means 13 million children were left 
uncovered who could have benefitted from this prevention method, with the identifiable reason 
being lack of funding.57 
Rapid Diagnostic Tests 
Rapid diagnostic tests (RDTs) have helped bridge the gap between prevention and 
treatment of malaria. RDTs provide a cost-effective alternative to diagnosis from clinical 
grounds or microscopy which are not always available in remote regions. Usually using a finger 
prick, RDTs detect specific proteins produced by malaria parasites in the blood of infected 
individuals.58 This allows individuals to seek out treatment when effected. From 2010-2016, 1.66 
billion RDTs were sold globally by manufacturers.  
  
                                                          
54 Per the WHO’s position of preventative therapies for Malaria for children 
55 Per the WHO’s position of preventative therapies for Malaria for children 
56 World Malaria Report, 20. 
57 World Malaria Report, xiv. 
58 Per WHO page How Malaria RDTs work 
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II.d. Treatment Methods 
Artemisinin-Based Combination Therapies 
For the treatment of uncomplicated malaria (malaria for which there are symptoms 
present but lacking in severity and organ dysfunction) from P. falciparum and P. vivax, the 
World Health Organization recommends artemisinin-based combination therapies (ACTs). WHO 
currently recommends 5 different ACTs -- the difference in treatment is dependent on the local 
strain that is present.59 ACTs involve the combination of “2 active ingredients with different 
mechanisms of action… [and] are the most effective antimalarial medicines available today.”60 
Proportionate use of ACTs has risen from a median of 39% in 2010-2012 to 54% in 2014-
2016.61  
For the treatment of severe malaria, injectable artesunate should be used for at least 24 
hours before administering a 3-day ACT treatment course (if the patient can ingest oral 
medicines).62 For children under 6, rectal artesunate should be given when injectable artesunate 
cannot be. The effectiveness of these treatments is contingent upon the artesunate administration 
being followed by a 3-day course of ACTs. As ACTs became the first-line treatment in 2014, 
“the number of courses of ACTs procured from manufacturers increased from 187 million in 
2010 to a peak of 393 million in 2013.”63 
 The WHO has documented plasmodium resistance to antimalarial drugs in 3 of the 5 
human-affecting species: P. falciparum, P. vivax and P. malariae. “Resistance” means a delayed 
                                                          
59 Per the WHO malaria treatment overview 
60 Per the WHO malaria treatment overview 
61 World Malaria Report, 27.  
62 Per the WHO malaria treatment overview 
63 Per the WHO malaria treatment overview 
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or incomplete clearing of the parasites from human blood that has been treated with antimalarial 
drugs. Resistance can include antimalarial resistance, artemisinin resistance, multidrug 
resistance, and treatment failure (improper dosage or poor drug quality, for example). While 
measuring the efficacy of these drugs is complex, antimalarial drugs have proven to be a highly 
effective method for treating malaria. Median treatment failure rates for effected and studied 
countries are usually below 10% with a few exceptions.64 As mentioned earlier, ACTs also 
function as a targeted preventative measure against malaria through SMC programs.  
Issues  
While insecticides and ACTs have proven to be effective measures in the past to curb the 
mortality rate of malaria, there is growing concern with the long-term effectiveness of these 
methods due to their selective pressures. This is largely because humans serve as the only 
significant infectious reservoirs for human malaria parasites.65 In other words, it does not take 
long for insecticide-resistant mosquitoes and drug-resistant parasites to reproduce and occupy 
greater proportions of the mosquito and parasite population.66 Karen Barnes and Nicholas White 
explain in 2005 in the journal Acta Tropica:  
After a steady decline in malaria deaths, the malaria mortality rate in eastern and southern 
Africa has increased dramatically in the last two decades, despite a drop in all-cause deaths 
among children (Snow et al., 2001; Korenromp et al., 2003). This increase is largely 
accounted for by the continued use of cheap and widely available drugs, chloroquine and 
                                                          
64 Per WHO’s Summary of treatment failure rates among patients infected with P. vivax, grouped by treatment and 
country and Summary of treatment failure rates among patients infected with P. falciparum, grouped by treatment 
and country 
65 Killen et al., Going beyond personal protection against mosquito bites to eliminate malaria transmission: 
population suppression of malaria vectors that exploit both human and animal blood, (BMJ Global Health, 2017). 
66 Koekemoer et al., Characterization of multiple insecticide resistance in Anopheles gambiae (Diptera: Culicidae) 
from Pointe Noire, Republic of the Congo, (Malaria Journal, 2010). 
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sulfadoxine-pyrimethamine, which have become progressively ineffective (Attaran et al., 
2004). Antimalarial resistance in Plasmodium falciparum parasites results in an enormous 
public health burden because of prolonged or recurrent illness, and progression to severe 
malaria, which is associated with increased hospitalisation and death… For example in 
Siaya, Western Kenya, 69% of malaria deaths are attributed to resistance to chloroquine 
treatment (Zucker et al., 2003).67  
It is difficult to assign efficacies and failure rates to any drug or method at large because 
of the geographical dependencies of such issues. Subsequently, these methods are still highly 
effective in certain regions and less effective in others. All things considered, though, and in light 
of these growing problems with prevention and treatment, it makes sense to look for a permanent 
solution. This has led to a surge in research towards malaria elimination. Our use of the term 
“elimination” will entail measures taken to eliminate the occurrence of malaria completely which 
would reduce and, ideally, eliminate the need for prevention and treatment methods.  
  
                                                          
67 Karen I. Barnes, Nicholas J. White, Population biology and antimalarial resistance: The transmission of 
antimalarial drug resistance in Plasmodium falciparum, Acta Tropica, Volume 94, Issue 3, 2005, Pages 230-240. 
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II.f. Elimination 
Gene Drives  
For 60 years, “gene drives” have served as a beacon of hope (and controversy) for 
antimalarial efforts. Now, they are becoming reality. A gene drive involves altering the genetic 
makeup of an organism to include a genetic characteristic not naturally found and utilizing 
various forms of technology to propagate that characteristic through a population.68 Unlike a 
typical genetic characteristic which would be passed down 50% of the time, gene drives are 
capable of forcing their way into 99% of offspring.69 One such example is the recently-
developed CRISPR--Cas9 -- a bacterial nuclease system that can be directed to use guide RNA 
to cut almost any DNA sequence with high specificity. The exact mechanisms by which gene 
drives like CRISPR (clustered, regularly interspaced, short palindromic repeats) operate and can 
be manipulated biologically are outside of the scope of what needs to be, and can be, covered 
here. The focus, rather, is on the potential application and risks.   
Oxitec’s Method 
Oxitec, an Oxford-based biotech startup, is utilizing gene drives in the attempt to 
eliminate the Aedes aegypti mosquito in certain areas of the world. Oxitec has developed 
genetically modified Aedes aegypti male mosquitoes whose offspring don’t develop past the 
larval stage.70 In other words, these mosquitoes occupy the reproductive capacity of a mosquito 
population and begin to quickly reduce the population due to the short lifespan of mosquitoes. 
This works via a “self-limiting gene” called the tTAV (tetracycline repressible transactivator 
                                                          
68 Bull & Malik, The gene drive bubble: New realities, (PLOS Genetics, 2017). 
69 Antonio Regaldo, The Extinction Intervention, (MIT Technology Review, 2016).   
70 Flavio Devienne Ferriera, Inside the Mosquito Factory That Could Stop Dengue and Zika, (MIT Technology 
Review, 2016).  
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variant) that is inserted into male mosquitoes. This gene variant, which only works in insect 
cells, causes offspring to create a non-toxic protein that “ties up the cell’s machinery so its other 
genes aren’t expressed and the insect dies.”71 See Appendix E for details. Oxitec is able to breed 
these mosquitoes in large quantities by feeding mosquitoes an antidote in the breeding facilities. 
This allows them to create effective breeding centers in local areas where the trials are 
conducted.  
Previous trials in Brazil, Panama, and the Cayman Islands have reduced the population of 
Aedes aegypti by more than 90% – a significant result compared to conventional mosquito-
killing methods, such as insecticides which only have a 30-50 per cent efficiency rate.72 Use of 
the method in Brazil, in particular, can be a good example. In April 2014, a year after the 
epidemic of dengue fever (transmitted by Aedes aegypti mosquitoes), Oxitec was brought in to 
run a limited trial. In 10 months of testing in two small neighborhoods of 5,600 residents, the 
number of cases fell from 133 annually to one case. In regards to ecology, the FDA published “a 
final finding of no significant impact (FONSI)” for Oxitec’s “self-limiting mosquito” methods.73  
It should be noted that the Aedes aegypti is not a primary carrier of malaria, especially in 
Africa -- that would be Anopheles mosquitoes. But, if this method continues to prove successful 
there would certainly be greater efforts to implement a similar method for Anopheles mosquitoes. 
In its current state, Oxitec’s method mirrors preventative measures in that it still requires 
reapplication. If, and when, it is developed to the point that it can be implemented once to kill a 
mosquito population and left be, then it can be fully considered an elimination method. This fits 
                                                          
71 Per Oxitec’s “Friendly Mosquitoes” page, see http://www.oxitec.com/our-solution/technology/the-science/  
72 Madhumita Murgia, Genetically-modified mosquitos released into the wild to wipe out offspring, (The Telegraph, 
2016).  
73 Per Oxitec’s program page, see http://www.oxitec.com/programmes/united-states/  
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into a greater narrative for gene drives to target and eliminate mosquitoes globally, though we 
are not quite at a point yet when that is feasible. 
Target Malaria 
Feasibility may be closer than previously thought, though. Target Malaria, an Imperial 
College project with 16 other institutions, has developed GM Anopheles gambiae mosquitoes 
which are used to implement two strategies. Anopheles gambiae is the most prominent malaria 
vector in Africa. One strategy focuses on using nucleases which target reproductive genes and 
cause female mosquitoes to become sterile. The other strategy is to skew mosquito reproduction 
to produce males.  
The Fertility strategy, as we’ll deem it, works as such: the nuclease identifies fertility 
genes, cuts through them, and offers itself to be used to repair the stretch of DNA. The altered 
gene does not affect fertility in females unless there are two modified genes present. Target 
Malaria’s modified mosquitoes, both male and female, each carry one copy of a chromosome 
with the nuclease and are able to reproduce normally. As the modified gene spreads through the 
population, females will naturally pick up two sets -- thus preventing their ability to reproduce. 
This allows a time-delay effect that can last up to 11 generations in order to let the gene drive 
spread through the population.74 
The Sex Biasing strategy, as we’ll call it, is based on reducing the number of female 
Anopheles gambiae which transmit malaria. Reducing the number of female mosquitoes in 
populations lowers transmission rates but also reduces the size of mosquito populations by 
constraining their reproductive capacity. It works as such: the nuclease is attached to the Y 
                                                          
74 See the Target Malaria page “Our Work,” https://targetmalaria.org/our-work/  
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chromosome in the sperm of male Anopheles gambiae and targets unique sections of the X 
chromosome to cut and fragment. In reproduction, this means only the in-tact Y chromosome can 
be passed on and the offspring will all be male. (Males have XY chromosomes and females have 
XX chromosomes.) Attaching the nuclease to the Y chromosome also makes the gene drive self-
sustaining since it stays attached to all the male offspring too. Target Malaria’s lab experiments 
show the ability to effectively alter the reproductive output to be 95% male and 5% female for a 
population.  
Target Malaria is backed by some big names. Notably, it has received $44 million in 
funding from the Bill and Melinda Gates Foundation, the largest investment into gene-drive 
research as of 2016.75 The Open Philanthropy Project also rewarded Target Malaria with a $17.5 
million grant.  
The implementation of Target Malaria’s methods may still be a ways down the road. 
According to a Gates Foundation business plan, the project could be ready to launch by 2029. Fil 
Randazzo, a deputy director at the Gates Foundation, outlined potential implementation where 
“buckets of mosquitoes” would be released every 50 kilometers which would begin the desired 
geographical and genetic chain reaction in a timeframe of roughly two years. Austin Burt, an 
evolutionary theorist and leader of Target Malaria, believes a drive could spread 5-20 kilometers 
per year from a release point and could be done with fewer than 500 mosquitoes. 76 From that 
point, there would remain only 1 percent of mosquitoes (based on their projections). Using nets 
and sprays while implementing a campaign of drug treatment to kill the parasitical reservoir 
would, in theory, break the malaria transmission cycle.  
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76 Antonio Regaldo, The Extinction Intervention 
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Other Potential Elimination Methods 
 There are a number of other new, promising methods from recent research that should be 
considered and potentially implemented when evidence from research and experimentation 
deems fit. One method is to disrupt mosquitoes’ ability to ‘smell’ humans. This method can be 
achieved through gene editing by disabling mosquitoes ability to detect humans via smell, 
though this has shown to have its difficulties as mosquitoes seem to have other biological work-
arounds in place for finding humans. Other versions of this bear more resemblance to insecticidal 
methods in terms of implementation and usage. Certain molecules and substances have been 
found to activate mosquitoes Orco coreceptors which can have the effect of flooding a 
mosquito’s olfactory system and disrupting its ability to detect humans. These methods aren’t 
currently ready for widespread implementation but they offer a targeted approach to preventing 
human infection without taking measures to necessarily kill mosquitoes. Helen Shen reviews it 
as such: 
Elucidating and learning to hack this complex system could pay off in a big way, as 
traditional insecticidal approaches have proven to be a “zero sum game,” Vosshall 
explained last November at the Society for Neuroscience annual meeting in San Diego. 
Multiple efforts since the 1960s have shown that under such extreme selective pressure, 
the animals rapidly evolve resistance to different pesticides.77 
Unfortunately, like other current methods, the selective pressure of this method would still favor 
the mosquitoes that are able to find humans in spite of the chemical effect. The resistant female 
                                                          
77 Helen Shen, How do mosquitoes smell us? The answers could help eradicate disease, (PNAS, 2017). 
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mosquitoes would lay the most eggs because they would be able to obtain the most blood to 
develop and nourish their eggs.    
Another method is to breed mosquitoes with specific bacteria that prevent it from 
carrying disease. A notable example is the Wolbachia bacteria, which, if present in Aedes aegypti 
mosquitoes, prevents the mosquito from carrying dengue, yellow fever, chikungunya, and Zika. 
The bacteria is passed between generations and, like other gene drive methods, creates a 
crowding-out effect which reduces the number of dangerous mosquitoes.78 The comparative 
benefit, though, is that it does not kill the second generation and therefore continues to 
exponentially crowd out dangerous mosquitoes since the bacteria is passed on. Conversely, this 
does little to eliminate mosquito populations if that is the overall goal.  
So what should the ultimate goal be? This is where we will dive into applying effective 
altruism to the antimalarial efforts we have laid out.   
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Chapter III: Application 
Prevention and Treatment Analysis 
Background 
As was mentioned in Part 2, preventative SMC programs did not reach the full population at 
risk of contracting malaria primarily because of a shortage of funding. Meanwhile, the Open 
Philanthropy Project also believes Target Malaria has funding bottlenecks are slowing progress. 
These issues hit the heart of what we hope to accomplish and the questions we seek to answer. Is 
there a way in which to make the funding go farther and better reduce Africa’s burden? Are 
certain antimalarial methods more viable and efficient than others -- and therefore more 
deserving of our funding than others? Are certain methods more ethical and does it matter? 
At the start of this project, I set out to build a unified model which integrated the relevant 
costs, efficacies, resistances, DALYs, and other factors of the different antimalarial methods. 
What I quickly discovered, though, is that building a model to deliver precise judgements meant 
I needed precise inputs. The inputs we currently have, sadly, are not sufficient to make such 
precise judgments; doing so, I would argue, would be irresponsible considering the ramifications 
of such decisions. For example, a misestimate of the rate at which parasites develop resistance 
could render certain prevention and treatment methods ineffective in parts of the world.  
Even beyond the ethical ramifications of building such a model, the complexity of this topic 
goes far beyond what is feasible to overcome at this level. Geographically, even small 
communities can have mosquito and parasite populations with drastically different levels of 
resistance to various methods. Risks associated with certain methods also vary with factors such 
as education. Collecting dynamic, up-to-date information on education in some of these regions 
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is frankly infeasible. Measuring the dollar return on R&D is also an extremely challenging 
prospect given the need to evaluate on an individual project level. Its results often go beyond the 
scope of one disease or method, too, as they can offer solutions for other areas of research. This 
doesn’t mean that comparing methods is hopeless, but, rather, that we will have to utilize 
quantitative analysis critically and rely on a heavier mix of qualitative analysis and expert 
opinion. We can start by evaluating some of the methods we detailed in Part 2. After evaluating 
the methods, I will make a recommendation on where we should continue to focus.  
Insecticidal Methods -- Nets and Spraying 
 Insecticide-treated bed nets (ITNs), long-lasting insecticidal nets (LLINs), and indoor-
residual spraying (IRS) utilize insecticides in order to repel and/or kill mosquitoes. These 
methods are non-targeted, meaning they are not designed such that their effects are only limited 
to mosquitoes, or specific mosquito species.  
There are a number of reasons that these methods, particularly nets, are commonly 
recommended by effective altruist organizations like GiveWell. First, insecticidal methods are 
cheap. As previously mentioned, the Against Malaria Foundation (AMF) can produce and 
distribute LLINs for an estimated $4.22 in most regions.79 With the WHO putting an estimated 
half of the world’s population at risk of contracting malaria, not to mention other mosquito-
delivered diseases, nets are an extremely effective way to start to help a significant amount of 
people. The WHO estimates that, in Sub-Saharran Africa alone, 54% of at-risk individuals are 
sleeping under an ITN. That means there is still significant capacity to distribute nets effectively 
before they become redundant. With an effective lifetime of 5 years, LLINs also can cover a 
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single child for the amount of time at which they are at the highest risk (0-5 years old). The 
distribution process is also very cost-efficient. Nets are lightweight and space-efficient (collapse 
to reduce wasted air space), and can be targeted to high-risk individuals by being given out at 
pregnancy and health clinics. In GiveWell’s 2018 Cost-Effective Analysis, the median estimate 
for cost per death averted (after accounting for leverage and funging) is $3,280 and $4,237 for 
children under-5. This is based specifically on the Against Malaria Foundation’s (AMF) pricing 
of distribution and efficacy. “Leverage,” in GiveWell’s usage, refers to “charities causing other 
entities to spend more on the program than they otherwise would have.” “Funging,” is the 
inverse of leverage; it is when they cause less spending from other entities. Consideration of 
these factors is a response to the “political blind spot” suggested by Emily Clough which we 
discussed in Part 1. GiveWell’s analysts estimated that donating to AMF nets has an 18% 
funging effect -- meaning the donation is 18% less cost effective than a stand-alone analysis. 
This is based on consideration of potential reactions of governments, the Global Fund, and 
unfunded distributions.  
These figures can help illustrate the impact of donations and intervention as it can be 
compared to other interventions, but we must still be skeptical of a unified quantitative metric. In 
November of 2016, GiveWell’s cost per death averted using AMF was $7,500. The last year and 
a half have not seen a significant change in pricing or efficacy that should drive this change -- 
especially in consideration that resistant is likely growing.80  
                                                          
80 See GiveWell 2018 cost-effectiveness analysis (‘Bed nets’ sheet, cells B91:92): 
https://docs.google.com/spreadsheets/d/1FApXxsBziIo2bcCFBMp9G3F7sDk0VRjzCETbP9J84TE/edit?usp=sharing 
And 2016 GiveWell cost-effectiveness analysis (‘Bed nets’ sheet, cells B78:80):   
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Williams  52 
 
Nets and spraying both have communal compounding effects, too. When 50% of a 
community utilizes nets, it has been found to create a coverage effect for the entire community. 
For IRS, the number is higher: 80% of households need to be sprayed to achieve the communal 
coverage effect. Spraying can be effectively implemented in public settings, though, to reduce 
the risk of contraction in higher-traffic areas. Compared to some other methods, insecticidal 
methods are also easier to understand. This means it is easier to educate communities and local 
health workers about how to properly utilize these methods and understand their risks. Nets and 
sprays also give people some agency the fight against malaria. Teaching a child the importance 
of using their bed nets at nights can reinforce at an early age how important it is to take action to 
protect oneself and to consider health risks.  
Insecticidal methods have their downsides, though. While using nets targets a time when 
people are most at risk (while they’re sleeping), it still doesn’t do much to protect children when 
they play outside, explore, and do all the things children enjoy doing. Nets also cannot protect 
women and mothers, among all individuals, as they go to get water for the family (keeping in 
mind that mosquitoes breed around stagnant water). IRS can help protect homes but has similar 
issues protecting people when they are outside. Nets are also not a targeted method -- i.e. they 
can affect other species in unintended ways. This could include flies and other insects that don’t 
pose a threat to humans; it could even include fish. As mentioned in Chapter 1 under Unintended 
Consequences, fishermen across the world, particularly in tropical areas like East Africa, have 
been using antimalarial bed nets to fish. Again, there isn’t causal data to show whether this is a 
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result of the growing availability of free nets, in particular. Regardless, there is sufficient 
information to know that this poses a health risk to both humans and the fish stocks.81  
 There is significant concern and growing research showing the growing resistance of 
mosquito species to insecticidal methods. Menno Smit, MD, a Ph.D. candidate at the Liverpool 
School of Tropical Medicine who led a new study on resistance, summarizes, “Since 2015, the 
number of annual deaths from malaria has stabilized. We're not making any more progress. We 
need new tools…"82 As my insights have largely been driven by WHO data from 2000-2015, this 
is a huge insight for recent trends. Smit points to a large issue with insecticidal methods: when 
these methods are implemented but mosquito populations aren’t eliminated, the selective 
pressures can quickly result in the proportionate population growth of resistant mosquitoes. In 
other words, if insecticides are prevalent, only the mosquitoes that are resistant will continue to 
take blood meals on humans and carry the population forward. Nets do have the benefit of still 
acting as a physical barrier between mosquitoes and humans at night, whereas resistance can 
make IRS a wasteful effort.  
Seasonal Malaria Chemoprevention 
Seasonal Malaria Chemoprevention (SMC) is one of the most cost-effective methods we 
have available to combat malaria. To quickly restate from earlier, SMC is the practice of 
providing children with full treatment courses of antimalarial drugs during malaria season in 
high transmission areas. This consists of four separate rounds of treatment. In 2016, 91% of 
children in areas where SMC programs were established received at least one round of treatment. 
                                                          
81 Damian Carrington, Global use of mosquito nets for fishing 'endangering humans and wildlife', The Guardian, 
2018.  
82 Nadia Whitehead, What If A Drug Could Make Your Blood Deadly To Mosquitoes?, NPR, 2018. 
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81% received two rounds, 69% received three rounds, and 51% received all four rounds.83 Per 
the WHO, each round protects a child for roughly one month. That left 13 million children 
completely uncovered on the basis of a lack of funding to scale it out.84   
GiveWell’s 2018 cost-effectiveness analysis puts the median cost per death averted via 
SMC at $2,280. This figure is excellent compared to other methods; it comes in lower than 
GiveWell’s estimated cost to save a life using AMF nets. Comparing these figures exactly isn’t a 
great idea, though, based on the amount of uncertainty of some figures. This is why it is more 
appropriate to organize methods into tiers, and undoubtedly SMC would join AMF nets in the 
top tier of options.  
As a method, SMC has a lot of advantages that allow it to be cost-effective. First, the 
drugs themselves are relatively cheap (we will discuss this in Treatment in the next section). 
Distributing them during malaria season allows their implementation to be limited to only times 
at which the method would be effective. This is the opposite of, say, bed nets which are present 
constantly throughout the year and are constantly degrading and wearing down. SMC also can be 
paired with almost any other preventative measure. One downside, though, is that it doesn’t 
necessarily reduce the need to implement nets and other prevention methods. For example, 
providing SMC for a region would not also preclude it from being an effective place to distribute 
nets in order to cover the contraction risk for the rest of the year, even though it is lower. 
Another reason for cost-effectiveness is that this method can be provided by community health-
workers after a small amount of training. GiveWell particularly recommends SMC programs run 
by the Malaria Consortium for their ability to actively scale up funding effectively in regards to 
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distribution and education. Additional funding is currently needed to expand programs to reach 
children in Nigeria, Chad, Burkina Faso, and Guinea Bissau.85 
There are few downsides, though, that are worth considering. Like many other methods, 
it contributes to the increase in plasmodium resistance. This works differently than the 
insecticidal methods which favor the resistance of mosquitoes. For SMC, only the parasites that 
are resistant to the drugs will survive inside of the human host. This means that the total 
population of people carrying malarial parasites would be carrying a strain with higher resistance 
that could then be spread. This is why it would be important to pair SMC with methods such as 
nets in order to reduce transmission.  
Treatment 
 The position on treatment is ethically much simpler from that of prevention. There is a 
substantial difference between the obligation to take preventative measures against any disease 
that doesn’t have an extremely high contraction rate and the obligation to treat people who have 
already contracted an illness. In the U.S. it would not be obligatory to extend me significant 
preventative measures against me contracting, say, a rhinovirus (common cause of the common 
cold), but if I showed up at a hospital seeking treatment, there would be an obligation to provide 
a best-effort treatment. (This doesn’t mean the U.S. would be unwise to take greater preventative 
measures that could reduce stress on the healthcare system, but that is another topic entirely.) 
Excluding cases of misdiagnosis, funds spent on treatment are theoretically 100% 
effective. This is in the context that all funding for treatment is applied to malaria cases whereas 
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funding for prevention may be spent on someone who never would have contracted malaria. It 
also, as mentioned before, may go towards distributing nets that are misused for other purposes 
such as fishing and don’t even contribute to the communal coverage effect. While it is important 
to scale up prevention methods, it shouldn’t be at the expense of treatment, even if prevention is 
cheaper. There may be a point at which this would not be true; say, for example, it cost $100,000 
to treat one case of malaria but only $1 to prevent it with 90% certainty. In these cases, if there 
was a possibility of shortage of funds for treatment, prevention may be the ethically acceptable 
decision. Thankfully, that is not the position we are in for malaria.  
Artemisinin-based combination therapy (ACT) dominates as the most prevalent and 
effective malaria treatment method and is the consensus recommendation of treatment among 
health organizations. ACTs are fairly cost-effective. There are lots of different price points based 
on the different combinations used; per the WHO for P. falciparum average cost per treatment 
success for different combinations range from US$2.95 to US$6.97. For P. vivax the most 
effective treatment had an average cost per treatment success of $0.18 and greater than a 99% 
probability of the cost per success being less than $1.00.86  
 
  
                                                          
86 Davis et al., Cost–effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data 
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III.b. Elimination and Modification 
Of all the methods discussed in this essay, I find those suggesting total elimination 
(specicide) or genetic modification to be the most interesting and worthy of discussion. Let’s 
start with the broad idea to kill all mosquitoes on the face of the earth using a gene drive. If it 
were feasible, and affordable, would it be worth undertaking? Or are the ethical and ecological 
implications too great for us to ever go through with it? From the effective altruist perspective, 
the argument would follow that it is worth eliminating mosquitoes once the benefits are greater 
than the costs and risks of making such a decision. If a gene drive was the most cost effective 
and risk-averse method to do so, then that would supersede other methods like insecticides. Of 
course, as we have discussed, it is impossible to actually know and quantify many of these 
factors. That is to say nothing of the ethical argument surrounding ‘specicide.’ Since eliminating 
mosquitoes would have a global impact, it presents a number of political and legal barriers such 
as: Which country or countries get to make the decision? Would it need to be unanimous among 
all countries? What if there are large dissenting groups of people within those countries? The list 
of political and legal challenges in undertaking such an initiative is overwhelming, to say the 
least, and, from a cynical perspective, impossible to answer properly. 
From an interview about genetic elimination, Andrea Crisanti, an Italian parasitologist 
and genetic engineer, was asked the question, “is it ethical to eliminate any part of nature on 
purpose?” He responded (including interviewer paraphrasing):  
 “Are you asking in a Darwinian way or a theological way? I think it’s a species 
competition between us and the mosquito. And I don’t think a species has the right to 
exist or not to exist.” He says what species do have is “fitness”—they have adapted to 
flourish in their environmental niche. For species we hope to save, we might use gene 
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drives to add beneficial genes, like ones for disease resistance. For species we despise, 
we can add ones that make them unfit for survival.87 
There is no correct answer to this question, as it relies on underlying moral philosophy -- and we 
have yet to find a unified and undeniable theory of moral philosophy.  
From a broad perspective, using gene drives on a global scale forces us to consider a 
number of risks and potential issues. First, it’s very possible that a gene drive, such as CRISPR, 
would fail due to the resistance of some mosquitoes. In their review, “The gene drive bubble: 
new realities,” James Bull and Harmit Malik assess: 
Simple changes in the target sequence can block the CRISPR nuclease, in turn reducing 
the rate at which heterozygotes become homozygotes. Champer et al. show that 
resistance to a CRISPR gene drive engineered in the germ line of D. melanogaster can 
arise rapidly, often in a single generation.88 
Concerns of resistance may be abated, though, by the possibility of combining drives. For 
example, the Target Malaria project has suggested combining several drives targeting three 
different DNA sites simultaneously. Tony Nolan, who works on the Target Malaria project, 
speculated that, “Mosquitoes might eventually evolve resistance to all three, but maybe not 
before they’re all dead.”89  
The ability to make these gene drives so powerful, though, is concerning in itself because it 
may make them harder to stop if and when we want to. Also, their potential to be applied to other 
species is no laughing matter; the FBI has been investigating the potential for gene drives to be 
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used as a bio-weapon against humans.90 There is concern that a genetic eradication campaign on 
this level could become a slippery slope. If we eradicate mosquitoes, can we eradicate any 
species we deem to have a negative impact? Does that negative impact have to be on the 
collective environment or just on humans? It wouldn’t take an overly critical eye to realize that 
as a species we haven’t always acted in the best interest of the environment up to now. Because 
of the impact these drives can have, the risk of accidental release has become a concern. In 
August of 2016, 27 scientists penned a letter to Science, a peer-review journal, urging for 
“stringent confinement strategies” and calling on scientists to refuse requests to share their 
genetically-modified organisms until some kind of rules had be figured out.91 The ability for 
small groups of people, even a team of two, to change an entire species using CRISPR and other 
gene drives should still be troubling. What happens when a team decides to bypass regulatory 
and legal roadblocks and decides to start releasing GM organisms from its lab into nature? Do 
we need to be policing scientists that in any way deal with gene drives?  
We must also consider the effect that adopting gene drive methods may have on donation-
based funding. Would people be less likely to support methods that they may disagree with 
ethically? Certainly some would. Could this be avoided by choosing methods that make 
mosquitoes sterile rather than methods that flip a “genetic kill switch?” Perhaps preventing 
mosquitoes from reproducing would be viewed as more acceptable than taking an active effort to 
kill the mosquito itself. If mosquitoes can feel pain (though there’s not much evidence that they 
do), then reproductive prevention seems like the more humane option of the two gene drives. 
This illustrates a strength and weakness of centralized donation foundations such as the Gates 
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Foundation: they can make investments that not all individuals would be comfortable funding. 
Of course, for those who support the methods this is a plus -- we can bypass the less-informed 
public opinion to utilize the most effective methods. On the other hand, centralized donation 
could also make unpopular choices that turn out to be wrong and have negative impacts on the 
very people who opposed them in the first place.  
All the issues mentioned up until now focus on the risks associated with gene drives even if 
we get them right. But what about the ecological impact of eliminating mosquitoes, specifically? 
This is an area of debate, and we cannot know for sure what the impact would be; what we 
should look to consider is whether the potential risks and uncertainty is significant enough to 
outweigh the current impact of mosquitoes. Not all mosquitoes bite humans; in fact, of the 
roughly 3500 named mosquito species only females from 6% of species bite humans.92  
Because males do not produce eggs and therefore need less energy, they are able to obtain 
sufficient energy from feeding on plant pollens. This makes them important pollinators across 
the globe. That being said, Janet McAllister, a medical entomologist for the CDC, says they 
aren’t crucial pollinators for any crops on which humans depend.93 Mosquito larvae are also an 
important food source for some animals such as frogs and fish. Per Richard Merritt, an aquatic 
entomologist cited in “Ecology: a world without mosquitoes,”: 
"Mosquitoes are delectable things to eat and they're easy to catch." In the absence of their 
larvae, hundreds of species of fish would have to change their diet to survive. "This may 
sound simple, but traits such as feeding behaviour are deeply imprinted, genetically, in 
those fish," says Harrison. The mosquitofish (Gambusia affinis), for example, is a 
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specialized predator — so effective at killing mosquitoes that it is stocked in rice fields and 
swimming pools as pest control — that could go extinct. And the loss of these or other fish 
could have major effects up and down the food chain.94 
Mosquitoes serve as a food source for bats and birds too, though there is much greater skepticism 
that they are significant for those species. This is because outside of larvae, mosquitoes only 
provide a very small amount of nourishment. For example, only 2% of the gut content of bats is 
comprised of mosquitoes; ecologists believe that bats and birds would quickly substitute 
mosquitoes with other insects -- particularly if other insects filled the ecological space left by 
mosquitoes.95 Perhaps one of the greatest, and least quantifiable, arguments is the possibility of 
gene drives “jumping” species to affect non-intended targets such as other insects or even 
humans. Species jumping hasn’t been observed yet but remains a commonly cited concern 
considering the theoretical possibility of these bacteria nuclease systems moving to other hosts. 
There is also evidence that eliminating one species of mosquito can lead to another species 
replacing their role as vector-carriers. For example, researchers in Jacksonville, Florida found 
that Asian tiger mosquitoes had inseminated yellow-fever mosquitoes -- effectively sterilizing 
them -- which allowed them to overtake their niche. Both mosquitoes are vector carriers.96 
 An interesting consideration is where mosquitoes currently serve as active barriers to 
negative human behavior. Science writer David Quammen has argued that mosquitoes have 
made tropical rainforests virtually uninhabitable to humans and delayed global deforestation. 
“Nothing has done more to delay this catastrophe over the past 10,000 years, than the mosquito,” 
Quammen says. Evaluating this claim brings to light why it is important to lay out what theory of 
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good we must use. From the good-for-the-universe point of view theory expressed in Schroeder’s 
Value Theory, which has also been deeply covered by a number of moral philosophers including 
Peter Singer, mosquitoes may actually be viewed positively based on this role of safeguarding 
the environment from humans. In my opinion, this actually exemplifies why we can’t use the 
good-for-the-universe point of view of good in order to guide antimalarial efforts. Based on the 
environmentally destructive impact of humans historically, this understanding of good would be 
further extended to recommend the end of all efforts to protect and extend human life. Any 
natural phenomenon, such as viruses and disease, would limit the destructive impact we would 
have. Such a recommendation is one that I am not willing to make, nor should we. For this 
reason, we will err on the side of a human-focused agglomerative theory while maintaining a 
consideration for other species and the environment at large. While there may also be intuition to 
think that the hundreds of thousands of lives saved may place a greater burden on already-
struggling communities, eliminating mosquitoes and malaria would likely reduce stress on 
healthcare systems and return some of the GDP loss associated with malaria (estimates are 
generally between 1% and 2% of GDP lost due to malaria) per Jeffrey Hii, a malaria scientist for 
the WHO.97 
Many arguments against eliminating the mosquito are focused on the global ecological 
impact of eliminating all mosquitoes. Most eradication campaigns currently considered, though, 
are focused on only a few species which largely impact humans. As mentioned, only females 
from 6% of mosquito species bite humans, and only half of these carry parasites that cause 
human disease. Of course, as we have seen, the impact of these 100 or so mosquito species is 
massive. We can abate some of the aforementioned criticisms against eradicating mosquitoes by 
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limiting our efforts to these particular species. By leaving most mosquito species in place, we 
can limit our effect on the ecology of many environments that are of concern. There is also 
reason to believe in the resilience of these environments. “We’re not left with a wasteland every 
time a species vanishes” says biologist Olivia Judson, who has called for targeted extinction of 
some mosquitoes.98  
Before diving into the specific campaigns currently under consideration or being employed, 
let’s lay out the reasons that support gene drive methods. First, because gene drives can be so 
narrowly targeted, this actually gives us a greater ability to only get rid of mosquitoes that harm 
humans while leaving others untouched. In particular this stands in comparison to widespread 
insecticidal campaigns because insecticides can be harmful to all mosquitoes as well as other 
species of insect. Of course, many mosquitoes are vectors for diseases other than malaria such as 
yellow fever and dengue, which are responsible for 703,902 and 75,572 DALYs, respectively, in 
Africa. This could be viewed as an advantage to both insecticidal and gene drive methods which 
can target mosquitoes which carry human-affecting diseases, but serves as a limitation to 
malarial medication methods such as SMC and general treatment.  
Another benefit to gene drives is that they don’t require a change in human behavior the way 
nets, sprays, and medication do. The ability of gene drives to be implemented and let to run their 
course helps highlight why other methods haven’t yet eliminated malaria. “Malaria is a problem 
of poverty, of instability and lack of political will. We are asking the drive to do what we can’t 
do politically or economically,” says Crisanti regarding the Target Malaria drive.99 Per Antonio 
Regaldo, a writer for the MIT Technology Review, in “The Extinction Invention”: 
                                                          
98 Bates, Would it be wrong to eradicate mosquitoes? 
99 Regaldo, The Extinction Intervention 
Williams  64 
 
“If it works, it will be incredibly cheap, easy to distribute, and egalitarian, benefiting 
everyone, rich or poor. It will also keep working once released, avoiding a common 
problem: often, the most difficult part of eradicating a disease is the endgame, when 
attention wanders elsewhere and spending per case skyrockets.”100 
We’ll delve later into evaluating the specifics of the Target Malaria project, but staying on gene 
drives broadly, Crisanti and Regaldo make good points. One potential issue with effective 
altruism is how to decide who receives the benefits of intervention. Say, for example, there are 
200 people at equal risk of malaria and they are all the same age. In other words, pretend the 
quantifiable DALYs are the same for all. Now assume that we can only distribute 100 nets, how 
can we decide who to help? Do we flip a coin? Gene drives can partially help overcome this 
issue. While we still may be faced with tough choices of which communities to start 
implementation in first, it leaves the chance of contraction to the natural probability of nature. In 
other words, we don’t have to make potentially discriminatory choices over who sees the greatest 
benefit.  
 Gene drives do not necessarily mean eliminating the mosquito, either. Modification 
without eradication may be a viable pathway with potentially fewer, albeit different, ethical 
concerns. On one hand, modification means we can avoid “specicide.” This helps overcome 
some of the ecological fears of eliminating mosquitoes. Yet, in a sense, modification can seem 
like a more slippery slope than elimination. Because the action is less extreme, it may be easier 
for us to justify modifying other species -- whereas we are much more hesitant to suggest 
annihilating another species (besides the mosquito) altogether. This could be because we have 
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eliminated, or tried to eliminate, species before -- both unintentionally and intentionally -- but 
have never attempted genetic modification of animals on a large scale. For example, humans 
have launched campaigns to eradicate mosquitoes when building the Panama Canal in the early 
1900s, larvacides in Brazil in the 1940s to fight malaria, DDT in the U.S. to rid the U.S. of 
malaria by 1949.101 Some possible methods for modification, as we introduced earlier, are 
modifying the ability of mosquitoes to “find” humans and making Aedes aegypti carriers of the 
Wolbachia bacteria which prevents them from carrying yellow fever, dengue, and zika. For some 
modification methods, the goal still seems to be to make it difficult for mosquitoes to bite 
humans. Preventing them from feeding would still have the same long-term effect that either the 
mosquito populations will die out, or they will adapt to overcome the modifications. We must 
therefore be wary of expensive methods that seek to promote the same consequence as more 
cost-effective alternatives.  
 Having laid out the broad reasons in support of and against elimination and modification 
of mosquitoes through genetic means, there are still a number of specific interventions to 
evaluate. Oxitec’s GM strategies in Brazil can serve as a good touchpoint to get an idea for cost-
effectiveness of gene drives that attempt to eliminate mosquito populations. In a two-
neighborhood trial, Oxitec says that to protect 5,600 people, it has been releasing three to four 
million mosquitoes a month. The company has not said how much the mosquitoes cost, but the 
government officials in Piracicaba, Brazil have said they expect to pay about 30 Brazilian reals, 
or $7.50 a year per person protected. That figure is approximately what the health department 
currently spends on sprays, larvicides, and associated costs like sick leave.102  
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This is more expensive per person than protection via a net, but it has unique advantages. 
First, the protection is not limited, theoretically, by location. I.e. while you have to be inside a 
net for it to be effective, this method extends coverage to every nook and cranny of the city. 
Additionally, the cost of this method should actually scale with the physical size of the city 
(square mileage) rather than the number of people therein. In other words, while a highly dense 
city would need more nets, high population density would actually increase the cost-
effectiveness of this method. If the method could reach a point that no longer needs consistent 
application, all the future lives in that area would also see the benefit of implementation.  
We must consider, though, that Oxitec is a for-profit company. Funding businesses rather 
than charities or governments may mean that certain areas that are viewed as less profitable for 
implementation are ignored. This could include areas without infrastructure like roads, areas 
where people are not clustered together, or areas where the governments cannot afford to pay for 
the service. Conversely, foreign aid could provide funding to target areas that can’t afford it 
while the business itself targets areas that can afford it (Brazil, Cayman islands, Florida, etc.). 
Additionally, we must consider whether the $7.50 figure is the actual cost of Oxitec’s strategy, or 
whether that is the markup for the service. The figure could even be below-cost in order to gather 
important trial data and showcase the value of the technology.   
 While Oxitec is targeting reduction of Zika, yellow fever, dengue, and chikungunya, 
Target Malaria offers a vision to a malaria-free world using gene drives. While it may not be 
ready until 2029,103 a representative has said that the Gates Foundation now views gene drives as 
“necessary” to end malaria and that it will be ready years before an effective vaccine could.104 
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Per the Open Philanthropy Project (OpenPhil), Target Malaria is the most likely project to 
develop a “fit-for-field construct first.”105 The project currently receives about $10 million per 
year in funding from the Gates Foundation to develop the gene drive technology itself for the 
Fertility and Sex Biasing strategies we outlined earlier. Despite being the largest research group 
working on a gene drive for malaria control, there is still room for effective funding to aid other 
areas of the project.  
 Using a basic analysis model built out by the Open Philanthropy Project, which I have 
updated to reflect recent figures, we can see the potential impact of donations to Target 
Malaria.106 The following is taken from my updated version of OpenPhil’s model: 
Quantity Estimate 
Size of Open Phil grant to support Target Malaria $18,700,000.00 
Rough cost per life saved by donating to AMF $3,280.00 
Projected number of lives saved by donating this amount to AMF 5701 
  
Malaria deaths per day in Sub-Saharan Africa 1717 
Discount for several factors** 10 
Estimated deaths averted per day of timeline acceleration 171.7 
Number of days of timeline acceleration required to equal lives saved via AMF 33.20 
 
Essentially what we see here is a series of calculations to see how many days OpenPhil’s grant of 
$18.7 million would need to speed up the timeline for Target Malaria in order to avert the same 
amount of deaths that the funding could achieve with AMF bed nets. The most interesting piece 
of the model is the “Discount for several factors” in the left column. This is OpenPhil’s effort to 
recognize that the current 1,717 daily deaths from IHME data would not be the same when 
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Target Malaria is finally deployed. Reaching the value of 10 came from discounting future funds 
by 3% annually. This means funds spent today for benefits in 10 years would be reduced by 
25%. Additionally, the malaria burden in 10 years will likely be smaller given the other current 
efforts we have discussed. It is also possible that Target Malaria will not be the project to 
actually launch the antimalarial gene drive first. These uncertainties are also factored into the 
cumulative discount of 10. This leads us to estimate that at the time this technology is ready, it 
could save 171.7 lives per day rather than the 1,717 that are currently lost per day. This means 
that accelerating the timeline by roughly 33 days would avert as many deaths as a present-day 
donation to AMF which has a rough cost per life saved of $3,280.  
This strikes at the core of what I discussed in the evaluation in Chapter I: a desire to make 
precise conclusions from imprecise data. This is not to say this model has no validity; to the 
contrary, I think it still effectively demonstrates the potential for funding to have a huge impact 
in saving lives through Target Malaria. The conclusion I would not be comfortable drawing, 
though, is that this demonstrates that we should abandon funding for other efficient causes.  
Thirty-three days doesn’t seem like a particularly absurd figure for $18.7 million to 
accelerate a timeline by in the context of 10 years. Let’s look where that money would go and 
see if that intuition holds true. The Gates Foundation primarily funds the gene drive research, 
which leaves funding needs in the following areas, per OpenPhil: 
1. Training graduate students and postdoctoral researchers in Burkina Faso, Mali, and 
Uganda 
2. Designing materials and funding outreach to key regulators 
3. Recruiting additional support to focus on shareholder engagement on an international 
level 
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4. Funding metagenomic analysis to better identify the ecological importance of the 
Anepholes gambiae  
5. Developing methods to facilitate easier rearing and release of modified mosquitoes (such 
as better sex sorting) 
6. Developing protocols that aim for maximally efficient release (conducting field trials) 
OpenPhil believes that some of these areas may be bottlenecking the project. While we can’t say 
for sure, it seems reasonable to think that $18.7 million could help accelerate processes such as 
the outreach to key regulators who could speed up regulation processes or be quicker to allow 
implementation of Target Malaria’s strategies. Even a few months, as we can see, could have 
substantial effects.  
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Chapter IV: Recommendation and Conclusion  
Recommendation 
In my research thus far, the only thing I can say with 100% certainty is that there is no 
one-size-fits-all solution to malaria. We face significant challenges including, to name a few: (1) 
the geographic differences as certain regions host different species of malaria vectors and 
parasites with varying resistance to different methods, (2) the difficulty of deriving factors to 
balance future impact vs present impact, and (3) the issues with using quantifiable comparison 
and metrics which can miss or ignore other important interventions such as education. That being 
said, my goal here has been to call attention to certain methods that generally appear to carry 
higher potential for effective intervention. In spite of these challenges, I think we can still do 
that. 
On the topic of education as a blind spot, I believe reducing health issues like malaria 
creates a foundation on which education can be built. When students are sick and schools aren’t 
safe havens from disease, the willingness to embrace education can be significantly hurt.  
Before all else, we must understand that a recommendation to move all funding to one 
method would be futile. Funding has marginal utility which decreases at a certain point for every 
additional dollar that can’t be utilized to its maximum potential. At some point, the funds are 
wasted and the alternatives become more effective. Additionally, there is value to taking a 
diverse approach. Much like how the Target Malaria project will likely implement multiple gene 
drives simultaneously to reduce the probability of mosquito resistance to all drives, we can say 
that utilizing a diverse approach in antimalarial efforts protects us from the downside risk that 
one method may fail.  
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While the value of research and development (R&D) is difficult to quantify, we can 
certainly see with growing resistance to treatments and insecticidal methods that research to 
counter this resistance and to create substantial gene drives could have a significant impact 
beyond the cost of conducting said research. At minimum, I would recommend that a steady 
percentage of total funding going towards malaria is applied to R&D which is focused on gene 
drives and countering mosquito and plasmodium resistance to current prevention and treatment 
methods. 
Outside of R&D, I would recommend that we continue to fund efforts that fall within the 
top cost-effective tier of evaluation. Particularly, LLIN distribution and SMC programs by AMF 
and the Malaria Consortium, respectively, are two charities within this top tier. With only 54% of 
at-risk individuals in sub-Saharan Africa sleeping under ITNs, there is still significant room for 
deployment and distribution of nets. I would recommend increasing funding to ramp up SMC 
programs. As we discussed, additional funding to the Malaria Consortium’s SMC programs 
could extend coverage to 13 million more children, particularly in Nigeria, Chad, Burkina Faso, 
and Guinea Bissau.  
As we saw from OpenPhil’s model, funding to gene drive projects like Target Malaria 
can have significant returns on par with other prevention methods even when only accelerating 
implementation by short amounts of time. I would recommend that early funding to Target 
Malaria go towards funding metagenomic analysis of the Anopheles gambiae in order to identify 
any potentially negative ecological impacts of the gene drive. This would give us enough time to 
potentially correct the method or else to implement counter-measures in order to sustain 
ecosystems. For example, if there was concern of reducing the mosquito as a food source to other 
animals, we could look at another gene drive which will expand another substitute insect 
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population to take over the space left by the mosquito. Hopefully this would occur naturally, but 
funding these studies would help us obtain a higher degree of certainty. While Target Malaria’s 
goal is to be implemented on a massive scale, late-stage trials (after safety is not a concern) 
should focus on high population density areas in order to stretch the cost-effectiveness and return 
from implementation. 
Considerations 
Of course, there are risks we must consider. While Target Malaria has pledged to work 
with local and national governments, and that the decision to implement the method will 
ultimately be up to them, is the project really prepared for countries to potentially reject the gene 
drive strategies they have developed? We have discussed the difficulty of containing such 
methods to borders; what could the results be from implementing in neighboring countries who 
disagree on its usage? What if, half-way through the expected 10 year timeline to launch Target 
Malaria, a better solution comes along? This, of course, should be factored into the discounts 
applied to valuing this method, but doing so accurately would be still rely on subjective factors.  
Conclusion 
 Malaria continues to impact the lives of millions, and disproportionately takes the lives of 
young children in sub-Saharan Africa. While there are a number of valid causes that fit within 
the top tier of worthiness, this is undoubtedly one of them. I am excited by the prospects ahead 
for solving and combatting the malaria crisis as we continue to better leverage available data and 
technology. In a time when we continue to solve some of the world’s most complex problems, I 
can’t help but feel that there is a group that has been left behind to suffer from one of the most 
preventable diseases in the world. While there are a number of ethical and practical hurdles we 
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must overcome in doing so, I am confident that a better future awaits us when we choose to do 
more good than less.  
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